<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Issues in HIV/AIDS in adults in palliative care</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Issues in HIV/AIDS in adults in palliative care</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Issues in HIV/AIDS in adults in palliative care</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Meera Pahuja, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jessica Merlin, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter A Selwyn, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">R Sean Morrison, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jane Givens, MD, MSCE</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3009004906"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Palliative care is an interdisciplinary medical specialty that focuses on preventing and relieving suffering and on supporting the best possible quality of life for patients facing serious illness and their families/loved ones. The primary tenets are symptom management; establishing goals of care that are in keeping with the patient's values and preferences; consistent and sustained communication between the patient and caregivers; and psychosocial, spiritual, and practical support, both to patients and their caregivers.</p><p>This topic review describes an approach to palliative care in patients with HIV/AIDS in resource-rich settings that is based on the available literature and our clinical experience. The specific areas in which palliative care principles and expertise might assist in the care of individuals with HIV infection include establishing goals of care, advance care planning (ACP), making decisions about continuing or discontinuing antiretroviral therapy (ART) as the end of life approaches, and symptom management.</p><p class="headingAnchor" id="H183641179"><span class="h1">OVERVIEW OF HIV STAGES AND TREATMENT</span><span class="headingEndMark"> — </span>HIV infection can be divided into the following stages:</p><p class="bulletIndent1"><span class="glyph">●</span>Viral transmission (see  <a class="medical medical_review" href="/z/d/html/3724.html" rel="external">"The natural history and clinical features of HIV infection in adults and adolescents", section on 'Viral transmission'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acute HIV infection (also called primary HIV infection or acute seroconversion syndrome) (see  <a class="medical medical_review" href="/z/d/html/3724.html" rel="external">"The natural history and clinical features of HIV infection in adults and adolescents", section on 'Acute and early HIV infection'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic HIV infection (see  <a class="medical medical_review" href="/z/d/html/3724.html" rel="external">"The natural history and clinical features of HIV infection in adults and adolescents", section on 'Chronic HIV infection without AIDS'</a> and  <a class="medical medical_review" href="/z/d/html/3724.html" rel="external">"The natural history and clinical features of HIV infection in adults and adolescents", section on 'AIDS and advanced HIV infection'</a>)</p><p></p><p>Antiretroviral therapy (ART) is recommended for all HIV infected individuals. The goal of ART is to inhibit viral replication, decreasing viral load and allowing the patient's immune system to recover. ART also decreases the risk and/or slows the development of AIDS-defining conditions and non-AIDS-defining complications  (<a class="graphic graphic_table graphicRef54622" href="/z/d/graphic/54622.html" rel="external">table 1</a>), lessens the risk of HIV transmission, and prolongs life. (See  <a class="medical medical_review" href="/z/d/html/3777.html" rel="external">"When to initiate antiretroviral therapy in persons with HIV"</a>.)</p><p>Modern ART generally consists of two or more drugs of different classes in combination to prevent the acquisition of drug resistance  (<a class="graphic graphic_table graphicRef60927" href="/z/d/graphic/60927.html" rel="external">table 2</a>). Many combinations are available in a single pill, which decreases the pill burden. Adherence is important because nonadherence can lead to viral replication in the presence of ineffective levels of one or more of the drugs used in the regimen, causing the virus to mutate and reducing susceptibility to current drugs used to treat HIV. (See  <a class="medical medical_review" href="/z/d/html/13978.html" rel="external">"Overview of antiretroviral agents used to treat HIV"</a>.)</p><p>Prophylactic antimicrobial therapy is administered to certain HIV-infected patients with the goal of preventing a clinically significant opportunistic infection. Such treatment is typically initiated as the individual's cell-mediated immunity (ie, CD4 cell count) declines. (See  <a class="medical medical_review" href="/z/d/html/3747.html" rel="external">"Overview of prevention of opportunistic infections in patients with HIV"</a>.)</p><p class="headingAnchor" id="H1748916394"><span class="h1">BURDEN OF HIV</span><span class="headingEndMark"> — </span>Globally, an estimated 39 million individuals are HIV infected, with 1.2 million of those in the United States [<a href="#rid1">1-3</a>]. (See  <a class="medical medical_review" href="/z/d/html/3036.html" rel="external">"Global epidemiology of HIV infection", section on 'Worldwide statistics'</a>.)</p><p>Advances in antiretroviral therapy (ART) have resulted in significant changes in the survival rate and quality of life of HIV-infected individuals. In resource-rich settings, HIV infected adults who are aware of their diagnosis, are linked to and stay in ongoing care, adhere to ART treatment, and are virologically suppressed have expected lifespans approaching that of the general population [<a href="#rid4">4-8</a>]. This increase in life expectancy is attributable to the decreased incidence of opportunistic infections because of early initiation of ART and improved care for those with HIV-related complications [<a href="#rid9">9-11</a>]. (See <a class="local">'Prognostication and the influence of ART'</a> below.).</p><p>However, a 2016 study conducted in the United States found that even with early treatment and access to care, an eight-year gap in life expectancy remained for HIV-infected compared with HIV-uninfected individuals. Lowest life expectancies were reached by HIV-infected individuals who were Black and had a history of injection drug use [<a href="#rid12">12</a>]. This highlights that although early ART initiation has impacted life-expectancies, racial disparities need to be addressed.</p><p>Increases in life expectancy have contributed to a rapidly aging HIV-infected population. A Dutch modeling study projected that the percentage of individuals with HIV over age 50 would increase from an already sizable 28 percent of the population in 2010 to 73 percent by 2030 [<a href="#rid13">13</a>]. Additionally, individuals of all ages with HIV are at risk for premature age-related comorbidities compared with the general population [<a href="#rid14">14</a>]. Therefore, despite gains in life expectancy, individuals with HIV shoulder a large burden of morbidity. (See <a class="local">'Comorbidity and multimorbidity'</a> below and  <a class="medical medical_review" href="/z/d/html/3735.html" rel="external">"HIV infection in older adults"</a>.)</p><p>Furthermore, despite advances in ART, complications of end-stage HIV disease are still prevalent because of undiagnosed cases and difficulties with adherence to ART and/or with retention in care. Roughly one-third of individuals living with HIV in the United States are diagnosed late in the disease course, at a time when they already have a CD4 count below 350 cells/microL or an AIDS-defining illness [<a href="#rid15">15</a>]. A 2019 Centers for Disease Control and Prevention (CDC) report found that of the 1.2 million Americans infected with HIV, only about half remain virally suppressed or undetectable [<a href="#rid16">16</a>].Risk factors associated with late diagnosis include substance use disorder (alcohol, intravenous drug use), depression, the stigma of HIV infection, lack of social support, and younger age [<a href="#rid17">17-21</a>]. The challenges inherent in managing these patients are discussed in more detail below. (See <a class="local">'Challenges in caring for patients with advanced HIV/AIDS'</a> below.)</p><p>Challenges also remain in resource-limited countries. Despite advances in ART provision in such settings, a large proportion of HIV-infected patients still do not have access to or are otherwise not receiving ART. Further, a 2022 study noted that of the 56.9 million patients with HIV who are in need of palliative care globally, only 7 million have access [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/13980.html" rel="external">"Use and impact of antiretroviral therapy for HIV infection in resource-limited settings"</a>.)</p><p class="headingAnchor" id="H1029762386"><span class="h2">Causes of death</span><span class="headingEndMark"> — </span>Despite advances in treatment, AIDS-defining illnesses cause a sizable proportion of deaths among HIV-infected individuals [<a href="#rid23">23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study examining mortality among 49,731 participants in the Data Collection of Adverse Events of HIV Drugs (D:A:D) study, the most common causes of death were AIDS-related causes (29 percent), followed by non-AIDS-related cancers (15 percent), liver disease (13 percent), and cardiovascular disease (11 percent) [<a href="#rid24">24</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study of 230 HIV-infected patients (89 percent with a prior AIDS-defining illness) in a United States palliative care program, 36 percent died of AIDS, 19 percent died of a non-AIDS-defining cancer, 18 percent died of bacterial pneumonia or sepsis, and 13 percent died of liver failure [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately 25 to 35 percent of all deaths in HIV-infected individuals are related to malignancies, especially non-Hodgkin lymphomas [<a href="#rid26">26,27</a>]. (See  <a class="medical medical_review" href="/z/d/html/8035.html" rel="external">"HIV infection and malignancy: Epidemiology and pathogenesis"</a>.)</p><p></p><p class="headingAnchor" id="H3504229266"><span class="h1">NEED FOR PALLIATIVE CARE</span><span class="headingEndMark"> — </span>In the early days of the HIV epidemic, all care for individuals with HIV-related disease was, by definition, palliative. With the introduction of tolerable, effective antiretroviral therapy (ART), HIV infection was transformed from a terminal disease with a uniformly poor prognosis to a serious chronic illness, at least in resource-rich settings among individuals who know their HIV status and are adherent to ART [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a> and  <a class="medical medical_review" href="/z/d/html/3724.html" rel="external">"The natural history and clinical features of HIV infection in adults and adolescents"</a>.)</p><p>However, even in the modern treatment era, individuals with HIV fit well within the "serious illness" paradigm for which early integration of palliative care plays a complementary role to active treatment of the underlying disease. These patients have a substantial burden of medical and psychiatric comorbidities, pain, and other symptoms throughout the course of the disease and a wide-ranging need for psychosocial, family, and care-planning support. It is possible that treatment of these comorbidities could improve HIV outcomes, such as adherence to ART, retention in HIV primary care, and virologic suppression.</p><p class="headingAnchor" id="H2679921239"><span class="h2">Comorbidity and multimorbidity</span><span class="headingEndMark"> — </span>Patients with HIV infection have a high degree of comorbidity and multimorbidity. Comorbidity, as it relates to HIV infection, can be defined as any disease or risk factor that interacts with HIV, making either condition worse [<a href="#rid29">29</a>]. Multimorbidity, which is defined by the World Health Organization (WHO) as two or more chronic health conditions [<a href="#rid30">30</a>], is an evolving concept in HIV disease. Multimorbidity is sometimes referred to as polypathology [<a href="#rid14">14</a>].</p><p>Compared with matched controls in the general population, individuals with HIV infection have higher rates of age-related comorbidities, such as hypertension, diabetes mellitus, renal failure, cardiovascular disease, and fractures, which occur an average of 10 years earlier [<a href="#rid14">14</a>]. Other common comorbidities include osteoporosis [<a href="#rid31">31</a>], frailty [<a href="#rid32">32,33</a>], liver disease [<a href="#rid34">34</a>], and neurocognitive impairment [<a href="#rid35">35</a>]. There is evidence to suggest that HIV and aging may interact to affect the brain and neurocognitive functions [<a href="#rid36">36</a>] (see  <a class="medical medical_review" href="/z/d/html/3723.html" rel="external">"HIV-associated neurocognitive disorders: Epidemiology, clinical manifestations, and diagnosis"</a>). These comorbid conditions are thought to be related to a myriad of factors, including direct toxicity from the virus, chronic inflammation, chronic immunosuppression, toxicity related to ART, and elevated rates of high-risk health behaviors in this population [<a href="#rid33">33,37-41</a>]. HIV-specific risk factors for developing comorbidities include lower nadir CD4 cell count and prolonged ART exposure. (See  <a class="medical medical_review" href="/z/d/html/3745.html" rel="external">"Primary care of adults with HIV", section on 'Monitoring for complications and preventive care'</a>.)</p><p>Notably, these medical comorbidities are in addition to the relatively high rates of psychiatric illness and substance use disorders in individuals with HIV infection [<a href="#rid42">42-45</a>]. As an example, in one study, rates of psychiatric illness were twice as high in individuals with HIV infection as in the general population [<a href="#rid46">46</a>]. Psychiatric comorbidities are associated with suboptimal adherence to ART [<a href="#rid47">47-49</a>]. In addition, studies of individuals with HIV infection have shown that patients with substance use disorders have worse health outcomes [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/z/d/html/4860.html" rel="external">"Overview of the neuropsychiatric aspects of HIV infection and AIDS"</a> and  <a class="medical medical_review" href="/z/d/html/4864.html" rel="external">"Depression, mania, and schizophrenia in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3725.html" rel="external">"Substance use disorder in patients with HIV"</a>.)</p><p class="headingAnchor" id="H2369327761"><span class="h1">CHALLENGES IN CARING FOR PATIENTS WITH ADVANCED HIV/AIDS</span></p><p class="headingAnchor" id="H3607670653"><span class="h2">Prognostication and the influence of ART</span><span class="headingEndMark"> — </span>Prognosis and disease trajectory in individuals with advanced HIV or AIDS are highly variable and depend on many factors, including the ability to successfully treat with antiretroviral therapy (ART), the immunologic response to ART, response to therapy for opportunistic infections, and the presence and type of malignancy, if present. Since many patients with advanced HIV/AIDS have not yet begun ART or have had past challenges with adherence or retention, the likelihood of long-term success of treatment of the acute condition in these patients is often uncertain. In our view, in the current treatment era, any attempt at prognostication that does not address whether the patient has had an adequate trial of ART would be ill-informed and inaccurate.</p><p>Some important prognostic indices for individuals with HIV have been developed from contemporary observational cohorts. These indices incorporate combinations of HIV-specific and non-HIV-specific biologic, behavioral, and demographic variables and offer prognostic information about risk and survival. For example, one of the most widely cited indices, the Veterans Aging Cohort Study (VACS) index, combines seven variables to predict mortality in HIV infected individuals: age, CD4 cell count, HIV viral load, hemoglobin, Fibrosis-4 Index [<a href="#rid51">51</a>], presence of hepatitis C, and glomerular filtration rate [<a href="#rid52">52-54</a>].</p><p>However, such indices neglect a critical factor in individuals with AIDS who are not on ART: ART can have a determinative impact on long-term survival. This is true even when patients present with advanced AIDS-related conditions that meet criteria for hospice admission, such as central nervous system toxoplasmosis or progressive multifocal leukoencephalopathy [<a href="#rid55">55</a>]. (See <a class="local">'Hospice'</a> below.)</p><p>In the current treatment era of potent ART, resistance to antiretroviral treatment leading to inability to find a fully active regimen is uncommon. Therefore, when individuals with HIV infection in resource-rich settings are dying of AIDS or AIDS-related illnesses, the root cause is typically a breakdown in what is known as the HIV treatment cascade. These patients are not taking ART because they are either unaware they have HIV and have been diagnosed with advanced disease, know they have HIV but are not linked to HIV care, or are linked to care but are not adherent to ART [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H171303055"><span class="h2">ART management in advanced disease</span><span class="headingEndMark"> — </span>Given the uncertainties with prognosis in the patient with advanced HIV/AIDS, which depends substantially on the success of ART, we recommend the following general approach to ART management in individuals with advanced HIV/AIDS:</p><p class="bulletIndent1"><span class="glyph">●</span>For individuals without an AIDS-defining illness who are not on ART due to late diagnosis or challenges with adherence or retention, every attempt should be made to fully engage them in care and begin ART, with close attention to adherence. (See  <a class="medical medical_review" href="/z/d/html/3777.html" rel="external">"When to initiate antiretroviral therapy in persons with HIV", section on 'Universal treatment'</a> and  <a class="medical medical_review" href="/z/d/html/3770.html" rel="external">"Patient monitoring during HIV antiretroviral therapy", section on 'ART Adherence'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For individuals with an AIDS-defining illness who are not on effective ART, we strongly recommend a trial of ART. ART should be initiated in consultation with an HIV specialist; the optimal time to initiate ART varies by clinical situation (see individual topic reviews for recommendations about initiation of ART in the setting of opportunistic infections). This trial should last for at least six months.</p><p></p><p class="bulletIndent1">In such patients, the short-term prognosis depends on the severity of the acute illness, particularly in cases such as cryptococcal meningitis requiring shunt placement, extensive Kaposi sarcoma, or <em>Pneumocystis</em> pneumonia requiring mechanical ventilation, which are associated with high mortality rates, even when treated aggressively. However, long-term prognosis typically depends not only on their acute medical issues but also upon whether patients can maintain lifelong retention in HIV primary care and adherence to ART. Since many patients with AIDS-related illnesses have not yet begun ART or have had past challenges with adherence or retention, the likelihood of long-term success in these patients is often uncertain.</p><p></p><p class="bulletIndent1">Determining with certainty which patients will be able to achieve long-term ART adherence, retention, and virologic suppression when they present with an AIDS-related illness is an impossible task. Therefore, it should be assumed that <strong>all</strong> individuals with HIV have the potential to achieve long-term success until clearly demonstrated otherwise.</p><p></p><p class="bulletIndent1">Frank conversations with patients and their families or loved ones in these situations are essential. Optimistic messages about availability of effective ART regimens should be communicated alongside the realities of the severity of the patient's acute illness and what would be necessary in order for the patient to achieve long-term success in terms of lifelong ART adherence and retention in HIV primary care.</p><p></p><p class="bulletIndent1">This discussion should prompt a discussion of the patient's goals of care. Some patients may have goals that focus on quality of life over quantity; other patients may be focused on treating the acute illness aggressively, regardless of the invasiveness of the treatments required; still others may fall somewhere in between. It is the provider's responsibility to respect the patient's choice, tailor the plan of care to the patient's goals, and revise the plan of care as often as necessary as these conversations evolve. A subspecialty palliative care consultation may facilitate these discussions. (See <a class="local">'Advance care planning'</a> below and <a class="local">'Primary versus secondary (subspecialty) palliative care'</a> below and  <a class="medical medical_review" href="/z/d/html/95552.html" rel="external">"Discussing goals of care"</a>.)</p><p></p><p class="bulletIndent1">It is important that all such patients have continuity, ideally with an experienced HIV primary care provider. Therefore, if such discussions occur in an inpatient setting, they should be done in consultation with an HIV specialist. Upon discharge, that specialist should facilitate the patient's linkage with outpatient HIV care and clearly communicate the patient's treatment plan as part of this hand-off.</p><p></p><p>Notably, the factors that lead to late diagnosis or that lead to suboptimal adherence to ART or retention in care include mental illness, substance use disorders, and lack of social support. These are serious comorbidities and concerns in and of themselves, and they can often continue to pose a barrier to restoring a patient's health. They should be addressed directly whenever possible.</p><p>In rare instances, high-level HIV drug resistance leaves a patient with no available fully active salvage regimen. Continuing a patient on a partially active regimen may control their disease enough to prolong their survival until a new drug or class of drugs is available. Occasionally, no such partially active regimen is available, and it may be appropriate to discontinue ART. This decision should be made in close consultation with an HIV specialist.</p><p>In general, once an individual is successfully on suppressive ART, they should continue it as long as it is consistent with the goals of care. Issues related to discontinuation of ART or prophylaxis at the end of life are discussed below. (See <a class="local">'Continuation versus discontinuation of HIV-related medications'</a> below.)</p><p class="headingAnchor" id="H3199178393"><span class="h1">UTILIZATION AND BENEFITS OF PALLIATIVE CARE</span><span class="headingEndMark"> — </span>The primary goal of palliative care is to improve quality of life for the patient and their family through relief of emotional and physical symptoms. Other key services are establishing goals of care that are based on the patient's values and preferences; advance care planning (ACP); psychosocial, spiritual, and bereavement support; and coordination of care. (See  <a class="medical medical_review" href="/z/d/html/14240.html" rel="external">"Benefits, services, and models of subspecialty palliative care"</a> and  <a class="medical medical_review" href="/z/d/html/86758.html" rel="external">"Palliative care and hospice outside of the United States"</a>.)</p><p>Empirical support for the benefit of early palliative care intervention in the management of serious illness comes from randomized trials showing that palliative care, when delivered alongside disease-modifying treatment, enhances quality of life, lowers the costs of care, and may improve survival. Much of the data are derived from patients with advanced cancer, but an increasing body of evidence supports the benefits of early palliative care intervention in a variety of diseases. (See  <a class="medical medical_review" href="/z/d/html/14240.html" rel="external">"Benefits, services, and models of subspecialty palliative care", section on 'Rationale for palliative care'</a>.)</p><p>Individuals with HIV infection in the modern treatment era fit well within the "serious illness" paradigm for which early integration of palliative care plays a complementary role to active treatment of the underlying disease for the following reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>Despite therapeutic advances, AIDS and its associated comorbidities remain important causes of death among patients infected with HIV. (See <a class="local">'Causes of death'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with HIV/AIDS often have a substantial burden of medical and psychosocial comorbidities, as well as pain and other symptoms, throughout the course of the disease. Additionally, the population of individuals with HIV is itself aging and has a high prevalence of comorbidity and multimorbidity. As patients survive longer, they may in fact have a greater need for comprehensive symptom management and a wide-ranging need for psychosocial, family, and care-planning support. (See <a class="local">'Comorbidity and multimorbidity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Uncertainty about prognosis and the limitations of ART (especially side effects and compliance) has made decision-making about ACP and end-of-life issues more complex and difficult than when the disease course was more uniform, rapid, and predictable [<a href="#rid57">57</a>].</p><p></p><p>In fact, both the World Health Organization (WHO) [<a href="#rid58">58</a>] and the Joint United Nations Program on HIV/AIDS (UNAIDS) [<a href="#rid59">59</a>] specify the importance of offering palliative care across the spectrum of illness for all patients with HIV/AIDS. (See  <a class="medical medical_review" href="/z/d/html/3745.html" rel="external">"Primary care of adults with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/4860.html" rel="external">"Overview of the neuropsychiatric aspects of HIV infection and AIDS"</a> and  <a class="medical medical_review" href="/z/d/html/3735.html" rel="external">"HIV infection in older adults"</a>.)</p><p>There is very little literature, especially in resource-rich settings, on the contemporary state of palliative care in individuals with HIV infection, and what data there are suggest that palliative and hospice care are underutilized in this population [<a href="#rid60">60</a>]. In one retrospective cohort study of 367 HIV patients hospitalized in a large urban safety-net hospital in 2010, 28 percent died during that hospitalization, but only 6 percent received a palliative care consultation, and 6 percent were enrolled in hospice. Of the patients who received hospice care, the mean time to death after enrollment was only 11 days.</p><p>While the benefits of specific palliative care interventions for individuals with HIV infection have not been tested in randomized controlled trials, early results from programs allowing for early integration of palliative care services into HIV primary care are promising [<a href="#rid56">56,61-67</a>]. As an example, one early systematic review included 17 studies evaluating outcomes or satisfaction with care in persons living with HIV who received services that specifically addressed symptom control, pain management, psychosocial support, and/or end-of-life care [<a href="#rid68">68</a>]. While acknowledging the significant methodologic challenges associated with the evidence base (one randomized trial, two observational studies with control groups, seven single-group longitudinal studies, and one cross-sectional study), the authors concluded that home palliative care and inpatient hospice programs resulted in better pain and non-pain symptom control, reduced anxiety and enhanced spiritual wellbeing, and improved disease insight. The sole randomized trial, which compared an integrated multidisciplinary home care approach with standard home care in 57 patients with AIDS, showed potentially meaningful benefits (in quality of wellbeing and survival), but the differences were not statistically significant [<a href="#rid69">69</a>].</p><p>An important point is that among the obstacles to ART adherence are lack of financial resources, housing instability, difficulties with transportation, and symptom burden, including fatigue, confusion, and pain [<a href="#rid63">63,70-72</a>]. Optimizing symptom control and addressing psychosocial issues that might impact treatment compliance are both elements of comprehensive palliative care. (See <a class="local">'ART management in advanced disease'</a> above and  <a class="medical medical_review" href="/z/d/html/2197.html" rel="external">"Overview of comprehensive patient assessment in palliative care"</a>.)</p><p>A "false dichotomy" between curative and palliative care in individuals with HIV has been described. However, optimally, palliative care should be delivered alongside potentially curative treatments. Individuals may receive life-prolonging treatment, such as treatment directed at the AIDS-related illness and/or ART, while also receiving treatment for pain and other symptoms, and engaging in goals of care conversations [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H1317599566"><span class="h2">Primary versus secondary (subspecialty) palliative care</span><span class="headingEndMark"> — </span>Hospice and Palliative Medicine is now recognized as a medical subspecialty by the American Board of Medical Specialties (ABMS), as well as in Canada, England, Ireland, Australia, and New Zealand. Many other European countries are also in the process of developing certification for palliative care. (See  <a class="medical medical_review" href="/z/d/html/86758.html" rel="external">"Palliative care and hospice outside of the United States"</a>.)</p><p>In many jurisdictions, palliative care is provided by specialists with advanced training in palliative care who work with a patient's other clinicians to provide an "extra layer" of support. Clinicians who are specifically trained in palliative care (subspecialty palliative care) can provide in-depth pain and symptom management, communication regarding goals of care, and care coordination across settings and over time. Subspecialty palliative care services are most available in high-income countries, as exemplified by the United States. The availability of subspecialty palliative care services in low-income countries is generally quite limited. (See  <a class="medical medical_review" href="/z/d/html/14240.html" rel="external">"Benefits, services, and models of subspecialty palliative care"</a> and  <a class="medical medical_review" href="/z/d/html/86758.html" rel="external">"Palliative care and hospice outside of the United States"</a>.)</p><p>Patients with all stages of HIV disease have complex care needs, including overlapping medical, psychiatric, and psychosocial comorbidities [<a href="#rid45">45</a>]. In order for a large number of patients with advanced life-threatening illness, such as HIV/AIDS, to benefit from palliative care, it is important that supportive services not only be provided by specialists but also be incorporated into the practices of all clinicians who are caring for individuals with HIV infection. Some term this "primary" palliative care to distinguish it from "secondary" or "subspecialty" palliative care [<a href="#rid73">73</a>]. Primary palliative care encompasses any type of supportive care that is delivered by all health care professionals caring for patients with serious life-threatening illness. The table gives some examples of domains within the skill sets of non-palliative-care clinicians as opposed to palliative care specialists  (<a class="graphic graphic_table graphicRef107897" href="/z/d/graphic/107897.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/106790.html" rel="external">"Primary palliative care"</a>.)</p><p>While primary care and infectious disease clinicians caring for patients with advanced HIV/AIDS are able to manage most of their patients' palliative care needs, consultation with a palliative care specialist may be beneficial in certain situations. Indications for a formal palliative care consultation have not been established for patients with advanced HIV/AIDS. However, general criteria for a palliative care assessment at the time of admission to the hospital are available  (<a class="graphic graphic_table graphicRef76969" href="/z/d/graphic/76969.html" rel="external">table 4</a>).</p><p>Optimal palliative care for patients with advanced HIV/AIDS should ideally incorporate both primary and subspecialty palliative care. Clinicians caring for these patients need to attain competence in providing comprehensive supportive care.</p><p class="headingAnchor" id="H1645160690"><span class="h2">What are the important components of palliative care?</span><span class="headingEndMark"> — </span>Important components of a comprehensive palliative care assessment include exploring the patient's understanding about his or her illness and prognosis; assessing and managing symptoms; counseling and establishing goals of care that are consistent with the patient's values and preferences; ACP; providing psychosocial, spiritual, and practical support, both to patients and their family caregivers; coordination across sites of care issues that are affecting access to and compliance with care; and helping plan end-of-life care, including determining the need and timing of hospice care. (See <a class="local">'Hospice'</a> below and  <a class="medical medical_review" href="/z/d/html/2197.html" rel="external">"Overview of comprehensive patient assessment in palliative care"</a>.)</p><p class="headingAnchor" id="H2910725255"><span class="h3">Assessing and managing symptoms</span><span class="headingEndMark"> — </span>Symptom burden, especially pain, is high for HIV-infected patients. As an example, in an analysis of data from 124 patients seen in an outpatient palliative care clinic embedded within an HIV primary care clinic, pain was the most common reason for referral (95 percent); most (90 percent) was chronic [<a href="#rid61">61</a>]. Other commonly addressed problems were depression (48 percent), anxiety (21 percent), insomnia (30 percent), and constipation (32 percent).</p><p>Symptom burden does not appear to be associated with CD4 cell count [<a href="#rid74">74,75</a>], except among patients with AIDS or CD4 cell counts &lt;200 cells/microL [<a href="#rid75">75,76</a>]. The relationship between symptom burden and viral load is less clear [<a href="#rid77">77</a>]. However, adherence to ART is associated with a lower symptom burden [<a href="#rid78">78,79</a>], while on the other hand a persistent symptom burden while on ART has been associated with reduced adherence to ART [<a href="#rid79">79</a>]. (See <a class="local">'ART management in advanced disease'</a> above.)</p><p>A comprehensive approach to symptom assessment in palliative care populations, including tools to measure symptom burden and intensity, is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2196.html" rel="external">"Approach to symptom assessment in palliative care"</a>.)</p><p>An approach to specific symptoms that are prevalent in late-stage HIV/AIDS (chronic pain, fatigue, fever, and anorexia/tissue wasting) is presented below. (See <a class="local">'Specific symptoms'</a> below.)</p><p class="headingAnchor" id="H1613548218"><span class="h3">Advance care planning</span><span class="headingEndMark"> — </span>ACP is the process of discussing choices and preferences for care at the end of life [<a href="#rid80">80</a>]. It includes general conversations about patient goals, values, and preferences, and more specific formal planning, such as creation of advanced directives (eg, drafting a living will, appointing a health care power of attorney). (See  <a class="medical medical_review" href="/z/d/html/86248.html" rel="external">"Advance care planning and advance directives"</a>.)</p><p>Discussing goals of care is an important component of ACP, and this starts with exploring what is important to the patient. Some patients feel that living as long as possible is most important, even if it means that they have to undergo highly burdensome interventions, such as prolonged mechanical ventilation, that impair their quality of life. Others may want to spend their remaining time at home with their loved ones, without having to go to the hospital, even if this compromises their survival. The best possible care should support patients in living the rest of their lives according to their informed wishes. A stepwise approach to the discussion of goals of care is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/95552.html" rel="external">"Discussing goals of care", section on 'REMAP: A stepwise approach'</a>.)</p><p>There are few prospective studies addressing disease-specific ACP for the palliative care needs of adult patients with HIV [<a href="#rid81">81</a>]. The evolving literature in the ART era suggests that ACP in individuals with HIV infection is highly variable, but in general patients with HIV/AIDS are less likely than HIV-uninfected individuals with other life-threatening illnesses to have discussed ACP with their health care providers [<a href="#rid82">82-89</a>]. One review of 11 studies of HIV-infected adults conducted between 1996 and 2015 found that between 8 and 47 percent had advance directives, and between 36 and 54 percent had some type of end-of-life communication [<a href="#rid89">89</a>]. Lack of ACP was most commonly associated with low income, followed by lower illness severity, low education level, being Black or Hispanic, female sex, younger age, injection drug use, and social isolation. A subsequent study identified having chronic pain, needing help with activities of daily living, and greater life satisfaction as being associated with ACP in individuals with HIV [<a href="#rid90">90</a>].</p><p>Other potential reasons for low rates of ACP in individuals with HIV/AIDS are the significant discrepancies between patients and health care providers with respect to what "end of life" really means in the context of HIV infection, the degree to which they believe that living a long life with HIV infection is possible, and their perspectives on patient autonomy in the decision-making process about end-of-life care [<a href="#rid91">91</a>]. A randomized trial of an intensive two-session ACP intervention tailored to individuals with HIV, which involved facilitation of goals-of-care discussions and selection of surrogate decision-maker, showed efficacy in improving rates of ACP completion and documentation in the medical record [<a href="#rid92">92</a>].</p><p class="headingAnchor" id="H1236126602"><span class="h4">When to initiate the discussion</span><span class="headingEndMark"> — </span>A major unresolved question is the optimal time to initiate discussion on ACP and preferences for end-of-life care in individuals with HIV infection. Some have pointed out that having these conversations too early can be problematic, as individuals' preferences change over time, and the concepts discussed can seem too abstract. On the other hand, having these conversations too late can result in receipt of care that does not match patient preferences or in the patient being too sick or cognitively impaired to actively participate in decision-making [<a href="#rid80">80</a>].</p><p>Therefore, finding the optimal time can be challenging but may be informed by the best available prognostic information [<a href="#rid80">80</a>]. However, as described above, prognostication in individuals with HIV infection who have the potential to get better with adherence to ART or who have multiple medical comorbidities may be especially challenging. (See <a class="local">'Prognostication and the influence of ART'</a> above.)</p><p>There is no formal guidance regarding when to initiate ACP discussions in individuals with HIV infection, and no consensus on this issue. Specifically, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Facademic.oup.com%2Fcid%2Farticle-lookup%2F58%2F1%2Fe1&amp;token=i%2BIJbZ3566jvLjqylaYc8D23O%2Fk2m8qRPrU4n4GJeOlCd9XderSkx9EoVSnSbVxy2qkUS95Vo9Y7GBj3ij0uzw%3D%3D&amp;TOPIC_ID=86295" target="_blank">Infectious Diseases Society of America HIV primary care guidelines</a> and the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.eacsociety.org%2Fguidelines%2Feacs-guidelines%2Feacs-guidelines.html&amp;token=%2FojvMRnG8olqqAXgAP7GAozLYDodMUledPwl0KbXkYz5onpdAJaKGPOXAkhIS82pab5BfPU0BCzR2qukfjhmtQ%3D%3D&amp;TOPIC_ID=86295" target="_blank">European AIDS Clinical Society</a> do not address ACP. However, based on our clinical experience, we recommend following the guidance of the well-established "Respecting Choices" paradigm [<a href="#rid93">93,94</a>], which recommends a three-stage, prognosis-informed approach, as outlined elsewhere. (See  <a class="medical medical_review" href="/z/d/html/86248.html" rel="external">"Advance care planning and advance directives", section on 'Facilitating ACP'</a>.)</p><p class="headingAnchor" id="H3351820265"><span class="h2">Challenges in end-of-life care</span><span class="headingEndMark"> — </span>In this section, we will discuss two major challenges that commonly arise in individuals with HIV infection at the end of life: continuation versus discontinuation of HIV-related medications, and HIV hospice entry criteria and their applicability in the current treatment era.</p><p class="headingAnchor" id="H1649872154"><span class="h3">Continuation versus discontinuation of HIV-related medications</span><span class="headingEndMark"> — </span>The shift towards end-of-life palliation often involves discontinuation of many disease-specific therapies. When disease-specific therapies contribute to comfort at the end of life, they may be continued after careful discussion with the patient and family. (See  <a class="medical medical_review" href="/z/d/html/14241.html" rel="external">"Palliative care: The last hours and days of life", section on 'Eliminating non-essential medications'</a>.)</p><p>For patients with HIV/AIDS who are approaching the end of life, one of the most important decisions is whether and when to discontinue ART. This is a particularly difficult decision for patients and their families/loved ones as it may be seen as "giving up." There are no guidelines to inform clinicians and patients about when to stop ART or routine prophylaxis for opportunistic infections, and one must weigh the risks (burdens such as cost, side effects, and pill burden) and benefits of continuing ART and opportunistic infection prophylaxis. Especially as more patients die from conditions such as liver failure or cancer (ie, dying with, rather than from, HIV/AIDS), decisions regarding the role of ART become more complex.</p><p>Each situation is unique; however, there are potential benefits for continuing ART, even in late-stage disease [<a href="#rid95">95</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In individuals who are virologically suppressed and dying from a condition besides AIDS, discontinuing ART will lead to uncontrolled viremia, which could contribute to symptom burden</p><p></p><p class="bulletIndent1">In the rare individual dying of AIDS and on a salvage ART regimen, even though this regimen may only be partially active in late-stage disease, treatment could select for a less "fit" virus, even in the presence of elevated viral loads [<a href="#rid57">57</a>]. This could help stave off burdensome symptoms (eg, fatigue, weight loss, neuropathy [<a href="#rid96">96</a>]) caused by the direct effects of the virus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ART may help sustain cognitive functioning, as systemic viral load does not always correlate with central nervous system viral load [<a href="#rid97">97,98</a>].</p><p></p><p>There are also many reasons to consider discontinuing ART or opportunistic infection prophylaxis:</p><p class="bulletIndent1"><span class="glyph">●</span>Continuing medications might contribute to anxiety for patients who had trouble taking medications prior to late-stage disease, cause confusion about goals, and distract from ACP [<a href="#rid57">57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pill burden and potential drug-drug interactions with common palliative care medications are also important to consider. For example, some antiretrovirals, such as <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a>, increase levels of some opioids (eg, <a class="drug drug_general" data-topicid="9729" href="/z/d/drug information/9729.html" rel="external">oxycodone</a>) while decreasing the levels of other opioids (eg, <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">methadone</a>) [<a href="#rid99">99</a>]. Patients should be monitored for signs and symptoms of overdose or withdrawal, and if needed the opioid dose should be adjusted.</p><p></p><p>Clinicians should initiate these discussions early with patients and their families/loved ones and continue the conversation about goals of care throughout the course of treatment.</p><p class="headingAnchor" id="H2005553683"><span class="h3">Hospice</span><span class="headingEndMark"> — </span>Hospice services in the United States are provided for patients who have an estimated life expectancy of six months or less under the Medicare hospice benefit. (See  <a class="medical medical_review" href="/z/d/html/2200.html" rel="external">"Hospice: Philosophy of care and appropriate utilization in the United States"</a>.)</p><p>Current hospice admission criteria are not evidence-based and were last written in 1996, prior to the introduction of modern ART; they are outlined in the table  (<a class="graphic graphic_table graphicRef111708" href="/z/d/graphic/111708.html" rel="external">table 5</a>). Non-disease-specific eligibility requirements, which must be used in conjunction with the disease-specific criteria, are outlined in the table  (<a class="graphic graphic_table graphicRef87321" href="/z/d/graphic/87321.html" rel="external">table 6</a>).</p><p>In our experience, providers may be reluctant to refer patients with AIDS who have any of these conditions to hospice given the prognostic uncertainty described above. (See <a class="local">'Prognostication and the influence of ART'</a> above.)</p><p>Another barrier to hospice referral in patients with AIDS is payment for ART. If the hospice diagnosis is AIDS, Medicare may not pay for ART. Despite these barriers, we assert that individuals with AIDS can be successfully referred to hospice. However, it is critical to work with a hospice that understands that goals of care and prognosis are in flux and, when needed, is willing to pay for ART. If the patient improves, they may be unenrolled from hospice.</p><p>In the current treatment era, comorbid conditions, rather than AIDS, may be the primary reason for referral to hospice. For example, an individual with HIV infection and cardiovascular disease might meet hospice criteria based on their New York Heart Association Class IV heart failure  (<a class="graphic graphic_table graphicRef52683" href="/z/d/graphic/52683.html" rel="external">table 7</a>) with significant symptom burden. Notably, in this situation, as the admitting diagnosis is heart failure, Medicare would still pay for ART.</p><p class="headingAnchor" id="H1818770012"><span class="h1">SPECIFIC SYMPTOMS</span></p><p class="headingAnchor" id="H2144459985"><span class="h2">Chronic pain</span><span class="headingEndMark"> — </span>Chronic pain is pain that lasts for more than three months, beyond the period of normal tissue healing [<a href="#rid100">100</a>]. Acute pain, such as pain that occurs with injury or acute inflammation, is an adaptive process that is necessary to alert the body to danger. However, pain that persists is the result of abnormal pain processing in the brain and spinal cord. A detailed discussion regarding the pathogenesis of chronic pain is presented separately. </p><p class="headingAnchor" id="H1027296224"><span class="h3">Epidemiology</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – Chronic pain is common in individuals with HIV infection. Although existing studies have significant methodologic limitations [<a href="#rid101">101</a>], the best evidence suggests that chronic pain affects 25 to 85 percent of individuals with HIV infection [<a href="#rid74">74,102-109</a>]. This is generally higher than prevalence estimates in the general population, which are closer to 10 to 15 percent [<a href="#rid110">110,111</a>]. There is also abundant evidence that chronic pain is often underdiagnosed and undertreated in this population [<a href="#rid112">112</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – Historically, pain in individuals with HIV infection was primarily neuropathic in origin. (See  <a class="medical medical_review" href="/z/d/html/3711.html" rel="external">"Epidemiology, clinical manifestations, diagnosis, and treatment of HIV-associated distal symmetric polyneuropathy (HIV-DSPN)"</a> and  <a class="medical medical_review" href="/z/d/html/3711.html" rel="external">"Epidemiology, clinical manifestations, diagnosis, and treatment of HIV-associated distal symmetric polyneuropathy (HIV-DSPN)", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1">However, this appears to be changing. Contemporary studies report a substantial burden of musculoskeletal pain in individuals with HIV/AIDS, which may be regional (eg, low back pain) or more widespread [<a href="#rid61">61,62,103,108,113</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated conditions</strong> – Co-occurring pain, mood disorders, and substance use disorder are common in HIV-infected patients. As in the general population, chronic pain in individuals with HIV has been strongly associated with mental illness, particularly depression, and substance use [<a href="#rid74">74,114,115</a>]. Despite clinician perception that patients may be reluctant to discuss the interplay between pain, mood, and substance use, the available evidence suggests that individuals with HIV infection are very aware of this connection and are able to clearly articulate it [<a href="#rid113">113</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Association with outcomes</strong> – Several studies have explored the relationship between chronic pain and outcomes in individuals with HIV/AIDS:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The relationship between chronic pain and adherence to antiretroviral therapy (ART) is unclear; some studies have suggested a strong relationship, while others have not [<a href="#rid78">78,102,104,116</a>]. A study examining the relationship between chronic pain in individuals with HIV and HIV outcomes, stratified by long-term opioid therapy prescription, reported that chronic pain was associated with virologic failure in individuals not prescribed long-term opioid therapy [<a href="#rid109">109</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Additionally, chronic pain in individuals with HIV is associated with significant functional impairment [<a href="#rid106">106</a>], up to 10 times greater odds in one study [<a href="#rid117">117</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No relationship has been found between chronic pain and mortality in individuals with HIV infection [<a href="#rid118">118</a>].</p><p></p><p class="headingAnchor" id="H1762636203"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>Given the high prevalence of chronic pain and the growing body of evidence linking chronic pain with outcomes in this patient population, individuals with HIV infection should be routinely and frequently asked about chronic pain. A brief chronic pain questionnaire has been tested in individuals with HIV and asks the following two questions: "How much bodily pain have you had during the last week (none, very mild, mild, moderate, severe, very severe)?" and "Do you have bodily pain that has lasted for more than three months?" [<a href="#rid101">101,119</a>]. Using these tools, chronic pain may be defined as at least mild or moderate pain for at least three months. For individuals who have chronic pain, a follow-up questionnaire to understand its functional impact, such as the Brief Pain Inventory-Short Form (<a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.npcrc.org%2Ffiles%2Fnews%2Fbriefpain_short.pdf&amp;token=d1E87fR%2BzD9gaRF8GHPU1UzwuJ%2BjFpML%2F%2Boo6E539bREITRC%2FJwpXm3gRM9SwP4VmYpgSAO2ox2ErR4inrQEsw%3D%3D&amp;TOPIC_ID=86295" target="_blank">BPI-SF</a>) [<a href="#rid120">120</a>] or its shorter version, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fhealth.gov%2Fhcq%2Ftrainings%2Fpathways%2Fassets%2Fpdfs%2FPEG_scale.pdf&amp;token=d7fChyviTVvLvXGIzVVq5jCbqJSY3SdBBWoI87mkTAIqwx8k3jIafm5F9efTznW3vmOFm4ats3tBnpgYap3JnX5bhv98I98P8Pks8LNUwck%3D&amp;TOPIC_ID=86295" target="_blank">PEG</a> (average <strong>p</strong>ain intensity, interference with <strong>e</strong>njoyment of life, and interference with <strong>g</strong>eneral activity) [<a href="#rid121">121</a>], is appropriate. (See  <a class="medical medical_review" href="/z/d/html/116196.html" rel="external">"Evaluation of chronic non-cancer pain in adults", section on 'Pain severity and impact'</a>.)</p><p>As with other patients with chronic pain, an evidence-based diagnostic evaluation should be performed, if consistent with the goals of care. No guidelines suggest that the presence of HIV should change the diagnostic paradigm. However, geriatric age in individuals with HIV is commonly considered to be 50 years old, and individuals with HIV have a higher prevalence of comorbid conditions, such as malignancies that may decrease the threshold for conducting additional testing [<a href="#rid122">122</a>]. Diagnostic evaluation of chronic pain is covered elsewhere. (See  <a class="medical medical_review" href="/z/d/html/116196.html" rel="external">"Evaluation of chronic non-cancer pain in adults"</a>.)</p><p class="headingAnchor" id="H1983501347"><span class="h3">Management</span><span class="headingEndMark"> — </span>The goal of managing chronic pain is improvement of both pain and physical function (such as the ability to work or be physically active), as well as emotional function [<a href="#rid123">123</a>]. These functional domains, as they relate to pain, can be measured with the PEG or BPI-SF, as described above. (See <a class="local">'Diagnosis'</a> above.)</p><p>In general, an approach to managing chronic pain should include initial psychoeducation about the nature of chronic pain as a chronic condition, setting expectations that the timeline for improvement is not days or weeks but rather months or years, and the importance of multimodal therapies. In our view and consistent with the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fmmwr%2Fvolumes%2F65%2Frr%2Frr6501e1.htm%3FCDC_AA_refVal%3Dhttps%253A%252F%252Fwww.cdc.gov%252Fmmwr%252Fvolumes%252F65%252Frr%252Frr6501e1er.htm&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLDUG08ZbGAJiu0qbyu%2F2zoJpMgyRlp2NrY3rJa1wBHNSSO4%2BkhJb7wu3ym8075isS8%2FiYELTR%2FHevy16Jt1jhjLY6ZMlmw5ZA9uxIGQfInghEPsbsy9Bwbr0Fy9NfZgWSw%3D%3D&amp;TOPIC_ID=86295" target="_blank">Centers for Disease Control and Prevention (CDC) Guideline for Prescribing Opioids for Chronic Pain</a> and the HIV Medicine Association guidelines on the management of chronic pain in patients with HIV, opioids should not be considered first-line treatment options for chronic pain; other modalities, such as physical therapy and cognitive behavioral therapy or supportive psychotherapy, should be tried first [<a href="#rid124">124</a>]. (See  <a class="medical medical_review" href="/z/d/html/93598.html" rel="external">"Use of opioids in the management of chronic non-cancer pain"</a> and  <a class="medical medical_review" href="/z/d/html/126111.html" rel="external">"Approach to the management of chronic non-cancer pain in adults"</a>.)</p><p>Few data are available to inform optimal management of chronic pain in this population. In a systematic review of pharmacologic and nonpharmacologic interventions for chronic pain in individuals with HIV infection, only 11 mostly low- or very low-quality studies were identified that met inclusion criteria [<a href="#rid125">125</a>]. The following were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>In two trials of anticonvulsants, neither <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> nor <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> was more effective than placebo for HIV-associated neuropathic pain [<a href="#rid126">126,127</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two randomized trials of a high-dose <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">capsaicin</a> patch versus placebo for HIV-infected patients with neuropathic pain found a greater reduction in pain on a numeric pain scale with intervention (mean reduction 22.8 versus 10.7 percent in one study and 31.2 versus 25.3 percent in the second) [<a href="#rid128">128,129</a>]. However, follow-up was limited to 12 weeks, and both studies allowed premedication with topical <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">lidocaine</a> and opioids for capsaicin-related pain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Only three low- or very low-quality studies investigated opioids, none of which found that opioids improved pain or function [<a href="#rid130">130-132</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Of the four studies of nonpharmacologic intervention, the only randomized trial examined inhaled cannabis versus placebo in patients with neuropathic pain, and follow-up was limited to one week. Median pain scores decreased twice as much with cannabis (34 versus 17 percent).</p><p></p><p>There has been increasing interest in cannabis for chronic pain in individuals with HIV. In the United States, both chronic pain and HIV are commonly listed as conditions allowable by state medical marijuana programs. Prospective studies of cannabis in individuals with HIV are limited to the short-term study described above. Two observational studies suggest a lack of association between cannabis and improvement in pain or reduction in the need for prescribed opioids [<a href="#rid133">133,134</a>]. The 2019 US Department of Health and Human Services HIV Guideline summarizes the conflicting evidence about cannabis-related harms in individuals with HIV, including cognitive impairment and reduced retention in care, and asserts that more research is needed before making recommendations to patients about cannabis use [<a href="#rid135">135</a>].</p><p class="headingAnchor" id="H13589981"><span class="h4">Limited use of opioids</span><span class="headingEndMark"> — </span>Over the past 10 years, it has become apparent that there is very limited evidence for the efficacy of opioids in improving pain and function in individuals with chronic non-cancer pain [<a href="#rid136">136</a>]. The risks of opioids include addiction, hypogonadism, falls, fractures, depression, cardiovascular risk, and greater risk of overdose-related death, among others. (See  <a class="medical medical_review" href="/z/d/html/93598.html" rel="external">"Use of opioids in the management of chronic non-cancer pain", section on 'Monitoring for adverse effects'</a>.)</p><p>The risks of opioid therapy for individuals with HIV infection generally parallel those experienced in the general population; however, some studies suggest that they may be exaggerated:</p><p class="bulletIndent1"><span class="glyph">●</span>Concerning behaviors that arise among individuals on long-term opioid therapy, such as lost or stolen prescriptions, aggressive behavior towards staff, or illicit substance use (which may represent a pain self-management strategy) are especially common in individuals with HIV infection [<a href="#rid137">137-139</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mortality may also be higher. One study of data from the Veterans Aging Cohort Study-Virtual Cohort (VASC-VC) for the year 2009 (which included 16,989 HIV-infected and 47,613 uninfected individuals) found that the risk of mortality in individuals on long-term opioid therapy was greater for those with HIV infection than for those without (hazard ratio [HR] 1.46, 95% CI 1.15-1.87, as compared with 1.25, 95% CI 1.05-1.49) [<a href="#rid140">140</a>].</p><p></p><p>In addition to these risks, there is also evidence that, as in the general population, individuals with HIV experience ongoing pain, despite opioid treatment [<a href="#rid141">141</a>], and those prescribed opioids experience higher emergency department utilization and hospitalization rates [<a href="#rid142">142</a>]. There is also evidence to suggest that HIV providers lack confidence in prescribing long-term opioids for chronic pain [<a href="#rid143">143</a>], and they worry that patients who are discontinued from long-term opioid therapy due to safety concerns (eg, ongoing substance use) may suffer worse retention in HIV primary care [<a href="#rid144">144</a>]. Adhering to guideline-concordant care can be a challenge; in one study, as compared with HIV uninfected patients, individuals with HIV were more likely to receive long-term opioids together with sedatives and were more likely to be prescribed long-term opioids in the setting of a substance use disorder [<a href="#rid145">145</a>].</p><p>Providers should carefully weigh the risks and benefits of opioids prior to prescribing and, if opioids are prescribed, at every visit thereafter. (See  <a class="medical medical_review" href="/z/d/html/93598.html" rel="external">"Use of opioids in the management of chronic non-cancer pain", section on 'Evaluation of risk prior to initiating therapy'</a> and  <a class="medical medical_review" href="/z/d/html/93598.html" rel="external">"Use of opioids in the management of chronic non-cancer pain", section on 'Initiating a trial of opioid therapy'</a> and  <a class="medical medical_review" href="/z/d/html/126633.html" rel="external">"Pharmacologic management of chronic non-cancer pain in adults", section on 'Opioids'</a>.)</p><p>Patients receiving chronic therapy for pain often experience episodes of acute pain, either because of a new injury or surgical procedure. Acute pain may also develop in patients who are receiving chronic opioid maintenance therapy for addiction or who are chronically using inappropriately prescribed or illegally obtained opioids. (See  <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">"Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"</a> and  <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management"</a>.)</p><p>The goals of treating acute pain in patients chronically using opioids are to prevent withdrawal, to provide adequate analgesia, and, for patients with a history of a substance use disorder, to avoid triggering a relapse or worsening of the addiction disorder. A stepwise approach to managing acute pain in such patients is described in detail elsewhere. In addition, patients who develop opiate use disorder should be treated when it develops. (See  <a class="medical medical_review" href="/z/d/html/83726.html" rel="external">"Management of acute pain in the patient chronically using opioids for non-cancer pain"</a>.)</p><p class="headingAnchor" id="H911272029"><span class="h2">Non-pain symptoms</span><span class="headingEndMark"> — </span>Even in the current treatment era, individuals with HIV infection experience a high burden of non-pain symptoms, both physical and psychological [<a href="#rid74">74,107,146,147</a>]. One illustrative study used a convenience sample of individuals with HIV infection from an urban clinic who were mostly well-controlled on ART [<a href="#rid74">74</a>]. Non-pain physical symptoms included lack of energy (57 percent), drowsiness (37 percent), sweats (34 percent), cough (33 percent), dry mouth (33 percent), diarrhea (31 percent), "I don't look like myself" (27 percent), feeling bloated (25 percent), dyspnea (25 percent), pruritus (24 percent), lack of appetite (23 percent), problems with sexual interest or activity (27 percent), and nausea (22 percent). Psychological symptoms were even more common and included worrying (63 percent), feeling sad (55 percent), difficulty sleeping (55 percent), feeling irritable (53 percent), feeling nervous (43 percent), and having difficulty concentrating (40 percent). When pain was included, patients reported a median of eight physical and psychological symptoms; 39 percent experienced high distress from three or more physical symptoms, and 48 percent of patients reported high distress from or high frequency of at least one psychological symptom.</p><p>In the early days of the HIV epidemic, non-pain physical symptoms were often due to an opportunistic infection or an AIDS-defining malignancy. However, in the modern treatment era, the etiology of these symptoms is less clear. In some cases, they may be due to other comorbid medical or psychiatric conditions (eg, dyspnea from chronic obstructive pulmonary disease [COPD], fatigue due to depression), or they may not have an easily identifiable cause. To illustrate this shift over time, selected symptoms experienced by individuals with HIV and their etiologies in the early HIV treatment era alongside etiologies in the current ART treatment era are summarized in the table  (<a class="graphic graphic_table graphicRef111811" href="/z/d/graphic/111811.html" rel="external">table 8</a>). We also include relevant management strategies for the purposes of comparison.</p><p>The following sections will focus on fatigue and anorexia/tissue wasting. Management of other common symptoms, including lipodystrophy, HIV-associated neurocognitive disorder (HAND), and neuropsychiatric issues in patients with HIV/AIDS, are covered in detail elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3733.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy"</a> and  <a class="medical medical_review" href="/z/d/html/3700.html" rel="external">"Treatment of HIV-associated lipodystrophy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3723.html" rel="external">"HIV-associated neurocognitive disorders: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/98405.html" rel="external">"HIV-associated neurocognitive disorders: Management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4860.html" rel="external">"Overview of the neuropsychiatric aspects of HIV infection and AIDS"</a> and  <a class="medical medical_review" href="/z/d/html/4864.html" rel="external">"Depression, mania, and schizophrenia in patients with HIV"</a>.)</p><p></p><p class="headingAnchor" id="H776685087"><span class="h3">Fatigue</span><span class="headingEndMark"> — </span>Fatigue is defined as the decreased capacity for initiating or maintaining physical activity; it may also be described by patients as "low energy." Fatigue is a common, often persistent symptom among individuals with HIV infection, with prevalence estimates of 30 to 80 percent [<a href="#rid148">148-150</a>]. (See  <a class="medical medical_review" href="/z/d/html/14239.html" rel="external">"Overview of fatigue in palliative care"</a>.)</p><p>Although considerable overlap occurs, fatigue is distinct from sleepiness, which is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/14892.html" rel="external">"Approach to the patient with excessive daytime sleepiness"</a>.)</p><p>Fatigue is likely multifactorial [<a href="#rid150">150</a>]. Physiologic factors associated with fatigue or fatigue severity in individuals with HIV infection include liver disease, hypothyroidism, hypogonadism, anemia, and duration of HIV infection [<a href="#rid150">150-152</a>]. An association with CD4 cell count and viral load is supported by some studies but not others [<a href="#rid150">150-152</a>]. In an earlier HIV treatment era, there was an association between ART and fatigue [<a href="#rid150">150</a>]; it is not clear whether this is still the case. Psychological and social factors associated with fatigue include stressful life events, depression, anxiety, posttraumatic stress disorder, and low income [<a href="#rid148">148,151,153</a>].</p><p>Fatigue in individuals with HIV infection interferes with physical, social, and mental functioning [<a href="#rid154">154</a>]; it may also interfere with adherence to ART [<a href="#rid155">155</a>]. An instrument to measure the severity and impact of fatigue in individuals with HIV infection has been developed (the HIV-related fatigue scale) [<a href="#rid156">156</a>].</p><p class="headingAnchor" id="H290557548"><span class="h4">Management</span><span class="headingEndMark"> — </span>In individuals with HIV infection, the approach to fatigue should be the same as in the general palliative care population. This includes a search for medical or psychiatric causes (especially hypogonadism), medication review, inquiry regarding the patient's sleep patterns, and treatment of the underlying cause, when present. <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">Testosterone</a> may help hypogonadal men with fatigue. Moderate exercise is a reasonable recommendation, if patients are able to tolerate it. (See  <a class="medical medical_review" href="/z/d/html/14239.html" rel="external">"Overview of fatigue in palliative care", section on 'Etiology'</a> and  <a class="medical medical_review" href="/z/d/html/14239.html" rel="external">"Overview of fatigue in palliative care", section on 'Clinical assessment'</a>.)</p><p>Several pharmacologic treatment approaches to fatigue have been investigated specifically in individuals with HIV infection, but none can be specifically recommended over another in this group [<a href="#rid157">157</a>]. In earlier treatment eras, <a class="drug drug_general" data-topicid="9981" href="/z/d/drug information/9981.html" rel="external">testosterone</a> [<a href="#rid158">158-160</a>] and stimulants, such as <a class="drug drug_general" data-topicid="9341" href="/z/d/drug information/9341.html" rel="external">dextroamphetamine</a> [<a href="#rid161">161</a>] and <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> [<a href="#rid162">162</a>], were studied with promising results. However, these studies were limited by small sample size and short duration of follow-up [<a href="#rid150">150</a>]. Testosterone has been shown to be of benefit for hypogonadal individuals who have fatigue [<a href="#rid158">158</a>]. (See  <a class="medical medical_review" href="/z/d/html/13969.html" rel="external">"Hypogonadism in males with HIV", section on 'Testosterone replacement therapy'</a>.)</p><p>Some benefit has been suggested for psychostimulants:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized placebo-controlled trial of <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">modafinil</a>, a central nervous system stimulant, in a predominantly virologically suppressed group of HIV-infected patients, 73 percent of individuals in the treatment arm reported improved fatigue at week 4 compared with 28 percent in the placebo arm; improvements were maintained at six months [<a href="#rid163">163</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A placebo-controlled trial of a closely related compound, <a class="drug drug_general" data-topicid="9260" href="/z/d/drug information/9260.html" rel="external">armodafinil</a>, yielded similar benefits in 70 patients with HIV [<a href="#rid164">164</a>]. The fatigue response rate to armodafinil was 75 versus 26 percent in the placebo arm.</p><p></p><p>A trial of a psychostimulant may be considered. However, given the high rate of comorbid psychiatric illness and substance use disorders among individuals with HIV, we recommend that <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">modafinil</a> and <a class="drug drug_general" data-topicid="9260" href="/z/d/drug information/9260.html" rel="external">armodafinil</a> be used with caution.</p><p>Studies of nonpharmacologic interventions, including cognitive behavioral therapy and relaxation techniques, showed promise in an earlier treatment era [<a href="#rid150">150</a>] but have not been conducted in contemporary populations of individuals with HIV infection.</p><p>The benefits of exercise in terms of improving physical performance have been shown in many trials conducted in patients with advanced cancer, although benefit in terms of fatigue has been more difficult to show. (See  <a class="medical medical_review" href="/z/d/html/14239.html" rel="external">"Overview of fatigue in palliative care", section on 'Exercise'</a>.)</p><p>There is a paucity of data on the benefits of exercise for HIV patients with fatigue. Efficacy and safety were addressed in two systematic reviews: one of progressive resistance exercise at all stages of HIV infection (seven studies, 294 participants [<a href="#rid165">165</a>]) and the other of aerobic exercise at all stages of HIV infection (14 studies, 454 participants [<a href="#rid166">166</a>]). In the first systematic review of resistance exercise, fatigue was considered as a primary outcome measure of cardiopulmonary fitness but was not reported in any of the included studies. In the second systematic review, only one of the included trials (n = 60 patients) found a significant decrease in fatigue in exercisers compared with non-exercisers, as measured by time on the treadmill, but none of the patients were in the advanced stage of illness. Despite the paucity of data, moderate exercise is a reasonable recommendation, if patients are able to tolerate it.</p><p class="headingAnchor" id="H1974026760"><span class="h3">Anorexia and tissue wasting</span><span class="headingEndMark"> — </span>Historically, weight loss and tissue wasting were common in HIV, particularly in the later stages of the disease. The incidence of wasting has declined since the introduction of ART [<a href="#rid167">167</a>]. Tissue wasting responds rapidly to ART, and the primary therapy for HIV wasting is initiation of ART for those who are not yet on treatment.</p><p class="headingAnchor" id="H670365804"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119531.html" rel="external">"Society guideline links: Palliative care"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/111624.html" rel="external">"Society guideline links: HIV treatment in nonpregnant adults and adolescents"</a>.)</p><p class="headingAnchor" id="H4186684645"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Need for palliative care </strong>– The introduction of tolerable, effective antiretroviral therapy (ART) has transformed HIV/AIDS from a terminal disease with a uniformly poor prognosis to a serious chronic illness, at least in high-resource settings. Individuals with HIV/AIDS fit well within the "serious illness" paradigm for which early integration of palliative care plays a complementary role to active treatment of the underlying disease. (See <a class="local">'Need for palliative care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Burden of HIV </strong>–<strong> </strong>Despite advances in ART, complications of end-stage HIV disease are still seen because of undiagnosed cases and difficulties with adherence to ART and/or with retention in care. AIDS-defining illnesses still cause a sizable proportion of deaths among HIV-infected individuals, and patients shoulder a large burden of morbidity because of the premature age-related comorbidities. (See <a class="local">'Burden of HIV'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>–<strong> </strong>Prognosis and disease trajectory in individuals with advanced HIV or AIDS are highly variable and depend on many factors that are both disease related and treatment related. Any attempt at prognostication that does not address whether the patient has had an adequate trial of ART is ill-informed and inaccurate. (See <a class="local">'Prognostication and the influence of ART'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiretroviral therapy (ART) </strong>–<strong> </strong>For individuals without an AIDS-defining illness who are not on ART, every attempt should be made to fully engage them in care and begin ART, with close attention to adherence. For individuals with an AIDS-defining illness who are not on effective ART, we strongly recommend a trial of ART in consultation with an HIV specialist. The optimal time to initiate ART varies by clinical situation. This trial should last for at least six months. (See <a class="local">'ART management in advanced disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Components of palliative care</strong> –<strong> </strong>Important components of a comprehensive palliative care assessment include exploring the patient's understanding about their illness and prognosis; assessing and managing symptoms; counseling and establishing goals of care that are consistent with the patient's values and preferences; providing psychosocial, spiritual, and practical support, both to patients and their family caregivers; coordination across sites of care issues that are affecting access to and compliance with care; and helping with advance care planning (ACP) and end-of-life care, including determining the need and timing of hospice care. (See <a class="local">'What are the important components of palliative care?'</a> above and  <a class="medical medical_review" href="/z/d/html/86248.html" rel="external">"Advance care planning and advance directives", section on 'Facilitating ACP'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>End-of-life care </strong>–<strong> </strong>Significant challenges to end-of-life care include decision-making about whether and when to stop HIV-related medications and when to refer for hospice care, given the significant prognostic uncertainty in most patients. (See <a class="local">'Challenges in end-of-life care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic pain </strong>–<strong> </strong>Chronic pain is common in individuals with HIV infection and includes both neuropathic and musculoskeletal pain. The goal of managing chronic pain is improvement of both pain and function (both physical and emotional). Given the paucity of evidence supporting benefit and increasing evidence about the harms of opioids in individuals with HIV infection, in our view, opioids should not be considered a first-line treatment option for chronic pain; other modalities, such as physical therapy, and cognitive behavioral therapy or supportive psychotherapy, should be tried first. (See <a class="local">'Chronic pain'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">UNAIDS. Global AIDS update, 2016. http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf.</li><li class="breakAll">HIV. The Global Health Observatory. World Health Organization. Available at: https://www.who.int/data/gho/data/themes/hiv-aids (Accessed on September 15, 2023).</li><li class="breakAll">Fast facts. HIV.gov. Available at: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics/ (Accessed on September 15, 2023).</li><li><a class="nounderline abstract_t">Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr 2010; 53:124.</a></li><li><a class="nounderline abstract_t">May MT, Gompels M, Delpech V, et al. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS 2014; 28:1193.</a></li><li><a class="nounderline abstract_t">Cowell A, Shenoi SV, Kyriakides TC, et al. Trends in hospital deaths among human immunodeficiency virus-infected patients during the antiretroviral therapy era, 1995 to 2011. J Hosp Med 2015; 10:608.</a></li><li><a class="nounderline abstract_t">Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300:51.</a></li><li><a class="nounderline abstract_t">Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013; 27:973.</a></li><li><a class="nounderline abstract_t">Djawe K, Buchacz K, Hsu L, et al. Mortality Risk After AIDS-Defining Opportunistic Illness Among HIV-Infected Persons--San Francisco, 1981-2012. J Infect Dis 2015; 212:1366.</a></li><li><a class="nounderline abstract_t">Schwarcz L, Chen MJ, Vittinghoff E, et al. Declining incidence of AIDS-defining opportunistic illnesses: results from 16 years of population-based AIDS surveillance. AIDS 2013; 27:597.</a></li><li><a class="nounderline abstract_t">Lima VD, Lourenço L, Yip B, et al. AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study. Lancet HIV 2015; 2:e92.</a></li><li><a class="nounderline abstract_t">Marcus JL, Chao CR, Leyden WA, et al. Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care. J Acquir Immune Defic Syndr 2016; 73:39.</a></li><li><a class="nounderline abstract_t">Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis 2015; 15:810.</a></li><li><a class="nounderline abstract_t">Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53:1120.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Vital signs: HIV testing and diagnosis among adults--United States, 2001-2009. MMWR Morb Mortal Wkly Rep 2010; 59:1550.</a></li><li class="breakAll">HIV surveillance reports. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html (Accessed on September 15, 2023).</li><li><a class="nounderline abstract_t">Mocroft A, Lundgren JD, Sabin ML, et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med 2013; 10:e1001510.</a></li><li><a class="nounderline abstract_t">Langebeek N, Gisolf EH, Reiss P, et al. Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med 2014; 12:142.</a></li><li><a class="nounderline abstract_t">Rebeiro P, Althoff KN, Buchacz K, et al. Retention among North American HIV-infected persons in clinical care, 2000-2008. J Acquir Immune Defic Syndr 2013; 62:356.</a></li><li><a class="nounderline abstract_t">Fleishman JA, Yehia BR, Moore RD, et al. Establishment, retention, and loss to follow-up in outpatient HIV care. J Acquir Immune Defic Syndr 2012; 60:249.</a></li><li><a class="nounderline abstract_t">Mugavero MJ, Lin HY, Willig JH, et al. Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis 2009; 48:248.</a></li><li><a class="nounderline abstract_t">Rangaraj A, Connor S, Harding R, et al. Advanced HIV disease and health-related suffering-exploring the unmet need of palliative care. Lancet HIV 2023; 10:e126.</a></li><li><a class="nounderline abstract_t">Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387.</a></li><li><a class="nounderline abstract_t">Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014; 384:241.</a></li><li><a class="nounderline abstract_t">Shen JM, Blank A, Selwyn PA. Predictors of mortality for patients with advanced disease in an HIV palliative care program. J Acquir Immune Defic Syndr 2005; 40:445.</a></li><li><a class="nounderline abstract_t">Gopal S, Patel MR, Yanik EL, et al. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst 2013; 105:1221.</a></li><li><a class="nounderline abstract_t">Rubinstein PG, Aboulafia DM, Zloza A. Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS 2014; 28:453.</a></li><li><a class="nounderline abstract_t">Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:651.</a></li><li><a class="nounderline abstract_t">Valderas JM, Starfield B, Sibbald B, et al. Defining comorbidity: implications for understanding health and health services. Ann Fam Med 2009; 7:357.</a></li><li><a class="nounderline abstract_t">Le Reste JY, Nabbe P, Rivet C, et al. The European general practice research network presents the translations of its comprehensive definition of multimorbidity in family medicine in ten European languages. PLoS One 2015; 10:e0115796.</a></li><li><a class="nounderline abstract_t">Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53:1130.</a></li><li><a class="nounderline abstract_t">Desquilbet L, Jacobson LP, Fried LP, et al. A frailty-related phenotype before HAART initiation as an independent risk factor for AIDS or death after HAART among HIV-infected men. J Gerontol A Biol Sci Med Sci 2011; 66:1030.</a></li><li><a class="nounderline abstract_t">Önen NF, Overton ET. A review of premature frailty in HIV-infected persons; another manifestation of HIV-related accelerated aging. Curr Aging Sci 2011; 4:33.</a></li><li><a class="nounderline abstract_t">Joshi D, O'Grady J, Dieterich D, et al. Increasing burden of liver disease in patients with HIV infection. Lancet 2011; 377:1198.</a></li><li><a class="nounderline abstract_t">Rodriguez-Penney AT, Iudicello JE, Riggs PK, et al. Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS 2013; 27:5.</a></li><li><a class="nounderline abstract_t">Aung HL, Aghvinian M, Gouse H, et al. Is There Any Evidence of Premature, Accentuated and Accelerated Aging Effects on Neurocognition in People Living with HIV? A Systematic Review. AIDS Behav 2021; 25:917.</a></li><li><a class="nounderline abstract_t">Glass TR, Ungsedhapand C, Wolbers M, et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med 2006; 7:404.</a></li><li><a class="nounderline abstract_t">Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005; 20:743.</a></li><li><a class="nounderline abstract_t">Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 2011; 8:12.</a></li><li><a class="nounderline abstract_t">Bedimo RJ, McGinnis KA, Dunlap M, et al. Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression. J Acquir Immune Defic Syndr 2009; 52:203.</a></li><li><a class="nounderline abstract_t">Walker Harris V, Brown TT. Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis 2012; 205 Suppl 3:S391.</a></li><li><a class="nounderline abstract_t">Galvan FH, Burnam MA, Bing EG. Co-occurring psychiatric symptoms and drug dependence or heavy drinking among HIV-positive people. J Psychoactive Drugs 2003; 35 Suppl 1:153.</a></li><li><a class="nounderline abstract_t">Pence BW, Miller WC, Whetten K, et al. Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States. J Acquir Immune Defic Syndr 2006; 42:298.</a></li><li><a class="nounderline abstract_t">Gaynes BN, Pence BW, Eron JJ Jr, Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. Psychosom Med 2008; 70:505.</a></li><li><a class="nounderline abstract_t">Halman M, Carusone SC, Stranks S, et al. Complex care needs of patients with late-stage HIV disease: a retrospective study. AIDS Care 2014; 26:320.</a></li><li><a class="nounderline abstract_t">Tegger MK, Crane HM, Tapia KA, et al. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDS 2008; 22:233.</a></li><li><a class="nounderline abstract_t">Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. J Acquir Immune Defic Syndr 2011; 58:181.</a></li><li><a class="nounderline abstract_t">Mellins CA, Havens JF, McDonnell C, et al. Adherence to antiretroviral medications and medical care in HIV-infected adults diagnosed with mental and substance abuse disorders. AIDS Care 2009; 21:168.</a></li><li><a class="nounderline abstract_t">Dalessandro M, Conti CM, Gambi F, et al. Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients. J Clin Psychopharmacol 2007; 27:58.</a></li><li><a class="nounderline abstract_t">Power R, Koopman C, Volk J, et al. Social support, substance use, and denial in relationship to antiretroviral treatment adherence among HIV-infected persons. AIDS Patient Care STDS 2003; 17:245.</a></li><li><a class="nounderline abstract_t">Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46:32.</a></li><li><a class="nounderline abstract_t">Justice AC, Holmes W, Gifford AL, et al. Development and validation of a self-completed HIV symptom index. J Clin Epidemiol 2001; 54 Suppl 1:S77.</a></li><li><a class="nounderline abstract_t">Justice AC, McGinnis KA, Skanderson M, et al. Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers. HIV Med 2010; 11:143.</a></li><li><a class="nounderline abstract_t">Justice AC, Modur SP, Tate JP, et al. Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr 2013; 62:149.</a></li><li class="breakAll">Taskforce. Saacmg.. Medical Guidelines for Determining Prognosis in Selected Non-cancer Disease, 2nd ed, The National Hospice Organization, Arlington, VA 1996.</li><li><a class="nounderline abstract_t">Merlins JS, Tucker RO, Saag MS, Selwyn PA. The role of palliative care in the current HIV treatment era in developed countries. Top Antivir Med 2013; 21:20.</a></li><li><a class="nounderline abstract_t">Selwyn PA, Forstein M. Overcoming the false dichotomy of curative vs palliative care for late-stage HIV/AIDS: "let me live the way I want to live, until I can't". JAMA 2003; 290:806.</a></li><li class="breakAll">World Health Organization policy on Palliative care in HIV/AIDS http://www.who.int/hiv/topics/palliative/PalliativeCare/en/.</li><li class="breakAll">Joint United Nations progam on HIV/AIDS (UNAIDS). AIDS palliative care: a techinical update. Geneva:UNAIDS; 2000. http://data.unaids.org/Publications/IRC-pub05/JC453-PalliCare-TU_en.pdf (Accessed on February 02, 2017).</li><li><a class="nounderline abstract_t">Rhodes RL, Nazir F, Lopez S, et al. Use and Predictors of End-of-Life Care Among HIV Patients in a Safety Net Health System. J Pain Symptom Manage 2016; 51:120.</a></li><li><a class="nounderline abstract_t">Perry BA, Westfall AO, Molony E, et al. Characteristics of an ambulatory palliative care clinic for HIV-infected patients. J Palliat Med 2013; 16:934.</a></li><li><a class="nounderline abstract_t">Johnson A, Condon KD, Mapas-Dimaya AC, et al. Report of an HIV clinic-based pain management program and utilization of health status and health service by HIV patients. J Opioid Manag 2012; 8:17.</a></li><li><a class="nounderline abstract_t">Lofgren S, Friedman R, Ghermay R, et al. Integrating early palliative care for patients with HIV: provider and patient perceptions of symptoms and need for services. Am J Hosp Palliat Care 2015; 32:829.</a></li><li><a class="nounderline abstract_t">Ruiz M, Cefalu C. Palliative care program for human immunodeficiency virus-infected patients: rebuilding of an academic urban program. Am J Hosp Palliat Care 2011; 28:16.</a></li><li><a class="nounderline abstract_t">Green K, Tuan T, Hoang TV, et al. Integrating palliative care into HIV outpatient clinical settings: preliminary findings from an intervention study in Vietnam. J Pain Symptom Manage 2010; 40:31.</a></li><li><a class="nounderline abstract_t">Wube M, Horne CJ, Stuer F. Building a palliative care program in Ethiopia: the impact on HIV and AIDS patients and their families. J Pain Symptom Manage 2010; 40:6.</a></li><li><a class="nounderline abstract_t">Harding R, Simms V, Alexander C, et al. Can palliative care integrated within HIV outpatient settings improve pain and symptom control in a low-income country? A prospective, longitudinal, controlled intervention evaluation. AIDS Care 2013; 25:795.</a></li><li><a class="nounderline abstract_t">Harding R, Karus D, Easterbrook P, et al. Does palliative care improve outcomes for patients with HIV/AIDS? A systematic review of the evidence. Sex Transm Infect 2005; 81:5.</a></li><li><a class="nounderline abstract_t">Nickel JT, Salsberry PJ, Caswell RJ, et al. Quality of life in nurse case management of persons with AIDS receiving home care. Res Nurs Health 1996; 19:91.</a></li><li><a class="nounderline abstract_t">Hardon AP, Akurut D, Comoro C, et al. Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa. AIDS Care 2007; 19:658.</a></li><li><a class="nounderline abstract_t">Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28:445.</a></li><li><a class="nounderline abstract_t">Roura M, Busza J, Wringe A, et al. Barriers to sustaining antiretroviral treatment in Kisesa, Tanzania: a follow-up study to understand attrition from the antiretroviral program. AIDS Patient Care STDS 2009; 23:203.</a></li><li><a class="nounderline abstract_t">Quill TE, Abernethy AP. Generalist plus specialist palliative care--creating a more sustainable model. N Engl J Med 2013; 368:1173.</a></li><li><a class="nounderline abstract_t">Merlin JS, Cen L, Praestgaard A, et al. Pain and physical and psychological symptoms in ambulatory HIV patients in the current treatment era. J Pain Symptom Manage 2012; 43:638.</a></li><li><a class="nounderline abstract_t">Lee KA, Gay C, Portillo CJ, et al. Symptom experience in HIV-infected adults: a function of demographic and clinical characteristics. J Pain Symptom Manage 2009; 38:882.</a></li><li><a class="nounderline abstract_t">Jaggers JR, Dudgeon WD, Burgess S, et al. Psychological correlates of HIV-related symptom distress. J Assoc Nurses AIDS Care 2014; 25:309.</a></li><li><a class="nounderline abstract_t">Lampe FC, Harding R, Smith CJ, et al. Physical and psychological symptoms and risk of virologic rebound among patients with virologic suppression on antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 54:500.</a></li><li><a class="nounderline abstract_t">Gay C, Portillo CJ, Kelly R, et al. Self-reported medication adherence and symptom experience in adults with HIV. J Assoc Nurses AIDS Care 2011; 22:257.</a></li><li><a class="nounderline abstract_t">Cooper V, Gellaitry G, Hankins M, et al. The influence of symptom experiences and attributions on adherence to highly active anti-retroviral therapy (HAART): a six-month prospective, follow-up study. AIDS Care 2009; 21:520.</a></li><li><a class="nounderline abstract_t">Billings JA, Bernacki R. Strategic targeting of advance care planning interventions: the Goldilocks phenomenon. JAMA Intern Med 2014; 174:620.</a></li><li><a class="nounderline abstract_t">Kimmel AL, Wang J, Scott RK, et al. FAmily CEntered (FACE) advance care planning: Study design and methods for a patient-centered communication and decision-making intervention for patients with HIV/AIDS and their surrogate decision-makers. Contemp Clin Trials 2015; 43:172.</a></li><li><a class="nounderline abstract_t">Mouton C, Teno JM, Mor V, Piette J. Communication of preferences for care among human immunodeficiency virus-infected patients. Barriers to informed decisions? Arch Fam Med 1997; 6:342.</a></li><li><a class="nounderline abstract_t">Wenger NS, Kanouse DE, Collins RL, et al. End-of-life discussions and preferences among persons with HIV. JAMA 2001; 285:2880.</a></li><li><a class="nounderline abstract_t">Erlandson KM, Allshouse AA, Duong S, et al. HIV, aging, and advance care planning: are we successfully planning for the future? J Palliat Med 2012; 15:1124.</a></li><li><a class="nounderline abstract_t">Ho VW, Thiel EC, Rubin HR, Singer PA. The effect of advance care planning on completion of advance directives and patient satisfaction in people with HIV/AIDS. AIDS Care 2000; 12:97.</a></li><li><a class="nounderline abstract_t">Hirschman KB, Abbott KM, Hanlon AL, et al. What factors are associated with having an advance directive among older adults who are new to long term care services? J Am Med Dir Assoc 2012; 13:82.e7.</a></li><li><a class="nounderline abstract_t">Alano GJ, Pekmezaris R, Tai JY, et al. Factors influencing older adults to complete advance directives. Palliat Support Care 2010; 8:267.</a></li><li><a class="nounderline abstract_t">Dobalian A. Advance care planning documents in nursing facilities: results from a nationally representative survey. Arch Gerontol Geriatr 2006; 43:193.</a></li><li><a class="nounderline abstract_t">Sangarlangkarn A, Merlin JS, Tucker RO, Kelley AS. Advance Care Planning and HIV Infection in the Era of Antiretroviral Therapy: A Review. Top Antivir Med 2016; 23:174.</a></li><li><a class="nounderline abstract_t">Hansen ED, Mitchell MM, Cruz Oliver DM, et al. Chronic Pain, Functional Status, and Life Satisfaction Are Associated With Patients Living With HIV Discussing Advance Care Planning With Their Family or Friends. J Pain Symptom Manage 2019; 57:961.</a></li><li><a class="nounderline abstract_t">Mosack KE, Wandrey RL. Discordance in HIV-positive patient and health care provider perspectives on death, dying, and end-of-life care. Am J Hosp Palliat Care 2015; 32:161.</a></li><li><a class="nounderline abstract_t">Lyon ME, Squires L, D'Angelo LJ, et al. FAmily-CEntered (FACE) Advance Care Planning Among African-American and Non-African-American Adults Living With HIV in Washington, DC: A Randomized Controlled Trial to Increase Documentation and Health Equity. J Pain Symptom Manage 2019; 57:607.</a></li><li><a class="nounderline abstract_t">Pecanac KE, Repenshek MF, Tennenbaum D, Hammes BJ. Respecting Choices® and advance directives in a diverse community. J Palliat Med 2014; 17:282.</a></li><li class="breakAll">Respecting choices http://www.gundersenhealth.org/respecting-choices/about-us/stages-of-planning (Accessed on December 07, 2015).</li><li class="breakAll">Fast Facts and cooncepts #102. Highly active antiretroviral therapy and hospice. Palliative Care Network of Wisconsin, June 2015 http://www.mypcnow.org/blank-ip7pk (Accessed on January 30, 2017).</li><li><a class="nounderline abstract_t">Simpson DM, Haidich AB, Schifitto G, et al. Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS 2002; 16:407.</a></li><li><a class="nounderline abstract_t">McArthur JC, McClernon DR, Cronin MF, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997; 42:689.</a></li><li><a class="nounderline abstract_t">Frenkel LM, Mullins JI. Should patients with drug-resistant HIV-1 continue to receive antiretroviral therapy? N Engl J Med 2001; 344:520.</a></li><li><a class="nounderline abstract_t">Gudin J. Opioid therapies and cytochrome p450 interactions. J Pain Symptom Manage 2012; 44:S4.</a></li><li class="breakAll">Merskey H, Bogduk, N. Part III: Pain terms, a current list with definitions and notes on usage. In: Classification of Chronic Pain, 2nd ed, IASP Task Force on Taxonomy, Merskey H, Bogduk, N (Eds), IASP Press, 1994.</li><li><a class="nounderline abstract_t">Merlin JS, Walcott MM, Herbey I, et al. Qualitative investigation of a Brief Chronic Pain Screening tool in HIV-infected patients. AIDS Patient Care STDS 2014; 28:176.</a></li><li><a class="nounderline abstract_t">Merlin JS, Westfall AO, Raper JL, et al. Pain, mood, and substance abuse in HIV: implications for clinic visit utilization, antiretroviral therapy adherence, and virologic failure. J Acquir Immune Defic Syndr 2012; 61:164.</a></li><li><a class="nounderline abstract_t">Miaskowski C, Penko JM, Guzman D, et al. Occurrence and characteristics of chronic pain in a community-based cohort of indigent adults living with HIV infection. J Pain 2011; 12:1004.</a></li><li><a class="nounderline abstract_t">Cervia LD, McGowan JP, Weseley AJ. Clinical and demographic variables related to pain in HIV-infected individuals treated with effective, combination antiretroviral therapy (cART). Pain Med 2010; 11:498.</a></li><li><a class="nounderline abstract_t">Silverberg MJ, Gore ME, French AL, et al. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study. Clin Infect Dis 2004; 39:717.</a></li><li><a class="nounderline abstract_t">Uebelacker LA, Weisberg RB, Herman DS, et al. Chronic Pain in HIV-Infected Patients: Relationship to Depression, Substance Use, and Mental Health and Pain Treatment. Pain Med 2015; 16:1870.</a></li><li><a class="nounderline abstract_t">Aouizerat BE, Miaskowski CA, Gay C, et al. Risk factors and symptoms associated with pain in HIV-infected adults. J Assoc Nurses AIDS Care 2010; 21:125.</a></li><li class="breakAll">Epidemiology of chronic pain in HIV-infected individuals.. In: Chronic Pand and HIV: A Practical Approach, Merlin JS, Selwyn PA, Treisman GJ, Giovanniello AG (Eds), Wiley-Blackwell, 2016.</li><li><a class="nounderline abstract_t">Merlin JS, Long D, Becker WC, et al. Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. J Acquir Immune Defic Syndr 2018; 79:77.</a></li><li><a class="nounderline abstract_t">Nahin RL. Estimates of pain prevalence and severity in adults: United States, 2012. J Pain 2015; 16:769.</a></li><li><a class="nounderline abstract_t">Von Korff M, Scher AI, Helmick C, et al. United States National Pain Strategy for Population Research: Concepts, Definitions, and Pilot Data. J Pain 2016; 17:1068.</a></li><li><a class="nounderline abstract_t">Ruiz M, Armstrong M, Ogboukiri T, Anwar D. Patterns of pain medication use during last months of life in HIV-infected populations: the experience of an academic outpatient clinic. Am J Hosp Palliat Care 2014; 31:793.</a></li><li><a class="nounderline abstract_t">Merlin JS, Walcott M, Ritchie C, et al. 'Two pains together': patient perspectives on psychological aspects of chronic pain while living with HIV. PLoS One 2014; 9:e111765.</a></li><li><a class="nounderline abstract_t">Tsao JC, Soto T. Pain in persons living with HIV and comorbid psychologic and substance use disorders. Clin J Pain 2009; 25:307.</a></li><li><a class="nounderline abstract_t">Malvar J, Vaida F, Sanders CF, et al. Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy. Pain 2015; 156:731.</a></li><li><a class="nounderline abstract_t">Berg KM, Cooperman NA, Newville H, Arnsten JH. Self-efficacy and depression as mediators of the relationship between pain and antiretroviral adherence. AIDS Care 2009; 21:244.</a></li><li><a class="nounderline abstract_t">Merlin JS, Westfall AO, Chamot E, et al. Pain is independently associated with impaired physical function in HIV-infected patients. Pain Med 2013; 14:1985.</a></li><li><a class="nounderline abstract_t">Tsui JI, Cheng DM, Quinn E, et al. Pain and Mortality Risk in a Cohort of HIV-Infected Persons with Alcohol Use Disorders. AIDS Behav 2016; 20:583.</a></li><li><a class="nounderline abstract_t">Merlin JS, Westfall AO, Chamot E, et al. Quantitative Evaluation of an Instrument to Identify Chronic Pain in HIV-Infected Individuals. AIDS Res Hum Retroviruses 2015; 31:623.</a></li><li><a class="nounderline abstract_t">Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994; 23:129.</a></li><li><a class="nounderline abstract_t">Krebs EE, Lorenz KA, Bair MJ, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. J Gen Intern Med 2009; 24:733.</a></li><li><a class="nounderline abstract_t">Molony E, Westfall AO, Perry BA, et al. Low back pain and associated imaging findings among HIV-infected patients referred to an HIV/palliative care clinic. Pain Med 2014; 15:418.</a></li><li><a class="nounderline abstract_t">Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003; 106:337.</a></li><li><a class="nounderline abstract_t">Bruce RD, Merlin J, Lum PJ, et al. 2017 HIVMA of IDSA Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With HIV. Clin Infect Dis 2017; 65:e1.</a></li><li><a class="nounderline abstract_t">Merlin JS, Bulls HW, Vucovich LA, et al. Pharmacologic and non-pharmacologic treatments for chronic pain in individuals with HIV: a systematic review. AIDS Care 2016; 28:1506.</a></li><li><a class="nounderline abstract_t">Hahn K, Arendt G, Braun JS, et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. J Neurol 2004; 251:1260.</a></li><li><a class="nounderline abstract_t">Simpson DM, Schifitto G, Clifford DB, et al. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. Neurology 2010; 74:413.</a></li><li><a class="nounderline abstract_t">Simpson DM, Brown S, Tobias J, NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology 2008; 70:2305.</a></li><li><a class="nounderline abstract_t">Clifford DB, Simpson DM, Brown S, et al. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr 2012; 59:126.</a></li><li><a class="nounderline abstract_t">Blinderman CD, Sekine R, Zhang B, et al. Methadone as an analgesic for patients with chronic pain in methadone maintenance treatment programs (MMTPs). J Opioid Manag 2009; 5:107.</a></li><li><a class="nounderline abstract_t">Newshan G, Lefkowitz M. Transdermal fentanyl for chronic pain in AIDS: a pilot study. J Pain Symptom Manage 2001; 21:69.</a></li><li><a class="nounderline abstract_t">Koeppe J, Lyda K, Johnson S, Armon C. Variables associated with decreasing pain among persons living with human immunodeficiency virus: a longitudinal follow-up study. Clin J Pain 2012; 28:32.</a></li><li><a class="nounderline abstract_t">Merlin JS, Long D, Becker WC, et al. Marijuana Use Is Not Associated With Changes in Opioid Prescriptions or Pain Severity Among People Living With HIV and Chronic Pain. J Acquir Immune Defic Syndr 2019; 81:231.</a></li><li><a class="nounderline abstract_t">Merlin JS, Patel K, Thompson N, et al. Managing Chronic Pain in Cancer Survivors Prescribed Long-Term Opioid Therapy: A National Survey of Ambulatory Palliative Care Providers. J Pain Symptom Manage 2019; 57:20.</a></li><li class="breakAll">AIDsinfo, US Department of Health Services. Clinical Guidelines. https://aidsinfo.nih.gov/guidelines (Accessed on August 02, 2019).</li><li><a class="nounderline abstract_t">Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015; 162:276.</a></li><li><a class="nounderline abstract_t">Hansen L, Penko J, Guzman D, et al. Aberrant behaviors with prescription opioids and problem drug use history in a community-based cohort of HIV-infected individuals. J Pain Symptom Manage 2011; 42:893.</a></li><li><a class="nounderline abstract_t">Knowlton AR, Nguyen TQ, Robinson AC, et al. Pain Symptoms Associated with Opioid Use among Vulnerable Persons with HIV: An exploratory study with implications for palliative care and opioid abuse prevention. J Palliat Care 2015; 31:228.</a></li><li><a class="nounderline abstract_t">Merlin JS, Walcott M, Kerns R, et al. Pain self-management in HIV-infected individuals with chronic pain: a qualitative study. Pain Med 2015; 16:706.</a></li><li><a class="nounderline abstract_t">Weisberg DF, Gordon KS, Barry DT, et al. Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients. J Acquir Immune Defic Syndr 2015; 69:223.</a></li><li><a class="nounderline abstract_t">Koeppe J, Armon C, Lyda K, et al. Ongoing pain despite aggressive opioid pain management among persons with HIV. Clin J Pain 2010; 26:190.</a></li><li><a class="nounderline abstract_t">Koeppe J, Lyda K, Armon C. Association between opioid use and health care utilization as measured by emergency room visits and hospitalizations among persons living with HIV. Clin J Pain 2013; 29:957.</a></li><li><a class="nounderline abstract_t">Lum PJ, Little S, Botsko M, et al. Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings. J Acquir Immune Defic Syndr 2011; 56 Suppl 1:S91.</a></li><li class="breakAll">Starrels JL, Peyser D, Fox AD, et al. HIV treatment providers' perspectives on opioid prescribing for chronic pain: The overriding concern to retain patients in care [oral abstract presentation]. Paper presented at: Association of Medical Education and Research in Substance Abuse, Bethesda MD, November 8, 2013.</li><li><a class="nounderline abstract_t">Gaither JR, Goulet JL, Becker WC, et al. Guideline-concordant management of opioid therapy among human immunodeficiency virus (HIV)-infected and uninfected veterans. J Pain 2014; 15:1130.</a></li><li><a class="nounderline abstract_t">McGowan J, Sherr L, Rodger A, et al. Effects of age on symptom burden, mental health and quality of life amongst people with HIV in the UK. J Int AIDS Soc 2014; 17:19511.</a></li><li><a class="nounderline abstract_t">Edelman EJ, Gordon K, Justice AC. Patient and provider-reported symptoms in the post-cART era. AIDS Behav 2011; 15:853.</a></li><li><a class="nounderline abstract_t">Barroso J, Leserman J, Harmon JL, et al. Fatigue in HIV-Infected People: A Three-Year Observational Study. J Pain Symptom Manage 2015; 50:69.</a></li><li><a class="nounderline abstract_t">Pence BW, Barroso J, Harmon JL, et al. Chronicity and remission of fatigue in patients with established HIV infection. AIDS Patient Care STDS 2009; 23:239.</a></li><li><a class="nounderline abstract_t">Jong E, Oudhoff LA, Epskamp C, et al. Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era. AIDS 2010; 24:1387.</a></li><li><a class="nounderline abstract_t">Barroso J, Hammill BG, Leserman J, et al. Physiological and psychosocial factors that predict HIV-related fatigue. AIDS Behav 2010; 14:1415.</a></li><li><a class="nounderline abstract_t">Payne BA, Hateley CL, Ong EL, et al. HIV-associated fatigue in the era of highly active antiretroviral therapy: novel biological mechanisms? HIV Med 2013; 14:247.</a></li><li><a class="nounderline abstract_t">Leserman J, Barroso J, Pence BW, et al. Trauma, stressful life events and depression predict HIV-related fatigue. AIDS Care 2008; 20:1258.</a></li><li><a class="nounderline abstract_t">Barroso J, Harmon JL, Madison JL, Pence BW. Intensity, chronicity, circumstances, and consequences of HIV-related fatigue: a longitudinal study. Clin Nurs Res 2014; 23:514.</a></li><li><a class="nounderline abstract_t">Al-Dakkak I, Patel S, McCann E, et al. The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis. AIDS Care 2013; 25:400.</a></li><li><a class="nounderline abstract_t">Pence BW, Barroso J, Leserman J, et al. Measuring fatigue in people living with HIV/AIDS: psychometric characteristics of the HIV-related fatigue scale. AIDS Care 2008; 20:829.</a></li><li><a class="nounderline abstract_t">Mücke M, Mochamat, Cuhls H, et al. Pharmacological treatments for fatigue associated with palliative care. Cochrane Database Syst Rev 2015; :CD006788.</a></li><li><a class="nounderline abstract_t">Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry 2000; 57:141.</a></li><li><a class="nounderline abstract_t">Knapp PE, Storer TW, Herbst KL, et al. Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss. Am J Physiol Endocrinol Metab 2008; 294:E1135.</a></li><li><a class="nounderline abstract_t">Rabkin JG, Wagner GJ, McElhiney MC, et al. Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. J Clin Psychopharmacol 2004; 24:379.</a></li><li><a class="nounderline abstract_t">Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000; 61:436.</a></li><li><a class="nounderline abstract_t">Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. Arch Intern Med 2001; 161:411.</a></li><li><a class="nounderline abstract_t">Rabkin JG, McElhiney MC, Rabkin R, McGrath PJ. Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. J Clin Psychiatry 2010; 71:707.</a></li><li><a class="nounderline abstract_t">Rabkin JG, McElhiney MC, Rabkin R. Treatment of HIV-related fatigue with armodafinil: a placebo-controlled randomized trial. Psychosomatics 2011; 52:328.</a></li><li><a class="nounderline abstract_t">O'Brien K, Nixon S, Glazier RH, Tynan AM. Progressive resistive exercise interventions for adults living with HIV/AIDS. Cochrane Database Syst Rev 2004; :CD004248.</a></li><li><a class="nounderline abstract_t">O'Brien K, Nixon S, Tynan AM, Glazier R. Aerobic exercise interventions for adults living with HIV/AIDS. Cochrane Database Syst Rev 2010; :CD001796.</a></li><li><a class="nounderline abstract_t">Dworkin MS, Williamson JM, Adult/Adolescent Spectrum of HIV Disease Project. AIDS wasting syndrome: trends, influence on opportunistic infections, and survival. J Acquir Immune Defic Syndr 2003; 33:267.</a></li></ol></div><div id="topicVersionRevision">Topic 86295 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : UNAIDS. Global AIDS update, 2016. http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.who.int/data/gho/data/themes/hiv-aids" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : HIV. The Global Health Observatory. World Health Organization. Available at: https://www.who.int/data/gho/data/themes/hiv-aids (Accessed on September 15, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics/" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Fast facts. HIV.gov. Available at: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics/ (Accessed on September 15, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19730109" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24556869" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26130520" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Trends in hospital deaths among human immunodeficiency virus-infected patients during the antiretroviral therapy era, 1995 to 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18594040" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Changes in the risk of death after HIV seroconversion compared with mortality in the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23698063" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26044289" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mortality Risk After AIDS-Defining Opportunistic Illness Among HIV-Infected Persons--San Francisco, 1981-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23079812" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Declining incidence of AIDS-defining opportunistic illnesses: results from 16 years of population-based AIDS surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25780802" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27028501" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26070969" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Future challenges for clinical care of an ageing population infected with HIV: a modelling study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21998278" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Premature age-related comorbidities among HIV-infected persons compared with the general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21124295" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Vital signs: HIV testing and diagnosis among adults--United States, 2001-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21124295" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Vital signs: HIV testing and diagnosis among adults--United States, 2001-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24137103" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25145556" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23242158" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Retention among North American HIV-infected persons in clinical care, 2000-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22531758" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Establishment, retention, and loss to follow-up in outpatient HIV care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19072715" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Missed visits and mortality among patients establishing initial outpatient HIV treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36427522" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Advanced HIV disease and health-related suffering-exploring the unmet need of palliative care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20380565" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25042234" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16280699" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Predictors of mortality for patients with advanced disease in an HIV palliative care program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23892362" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24401642" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19640227" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19597174" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Defining comorbidity: implications for understanding health and health services.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25607642" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The European general practice research network presents the translations of its comprehensive definition of multimorbidity in family medicine in ten European languages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21998280" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21719610" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A frailty-related phenotype before HAART initiation as an independent risk factor for AIDS or death after HAART among HIV-infected men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21204781" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A review of premature frailty in HIV-infected persons; another manifestation of HIV-related accelerated aging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21459211" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Increasing burden of liver disease in patients with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23305257" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33025390" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Is There Any Evidence of Premature, Accentuated and Accelerated Aging Effects on Neurocognition in People Living with HIV? A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16903986" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15741212" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21221855" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19617846" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22577213" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12825758" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Co-occurring psychiatric symptoms and drug dependence or heavy drinking among HIV-positive people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16639343" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders in an HIV clinic in the Southeastern United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18378865" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23869624" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Complex care needs of patients with late-stage HIV disease: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18290749" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21857529" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19229685" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Adherence to antiretroviral medications and medical care in HIV-infected adults diagnosed with mental and substance abuse disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17224714" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12816618" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Social support, substance use, and denial in relationship to antiretroviral treatment adherence among HIV-infected persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17567829" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11750213" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Development and validation of a self-completed HIV symptom index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19751364" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23187941" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23187941" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23596275" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The role of palliative care in the current HIV treatment era in developed countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12915434" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Overcoming the false dichotomy of curative vs palliative care for late-stage HIV/AIDS: "let me live the way I want to live, until I can't".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12915434" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Overcoming the false dichotomy of curative vs palliative care for late-stage HIV/AIDS: "let me live the way I want to live, until I can't".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12915434" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Overcoming the false dichotomy of curative vs palliative care for late-stage HIV/AIDS: "let me live the way I want to live, until I can't".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26384554" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Use and Predictors of End-of-Life Care Among HIV Patients in a Safety Net Health System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23477304" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Characteristics of an ambulatory palliative care clinic for HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22479881" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Report of an HIV clinic-based pain management program and utilization of health status and health service by HIV patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25216735" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Integrating early palliative care for patients with HIV: provider and patient perceptions of symptoms and need for services.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20543161" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Palliative care program for human immunodeficiency virus-infected patients: rebuilding of an academic urban program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20619211" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Integrating palliative care into HIV outpatient clinical settings: preliminary findings from an intervention study in Vietnam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20619204" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Building a palliative care program in Ethiopia: the impact on HIV and AIDS patients and their families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23113572" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Can palliative care integrated within HIV outpatient settings improve pain and symptom control in a low-income country? A prospective, longitudinal, controlled intervention evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15681714" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Does palliative care improve outcomes for patients with HIV/AIDS? A systematic review of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8606987" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Quality of life in nurse case management of persons with AIDS receiving home care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17505927" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11744832" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19866538" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Barriers to sustaining antiretroviral treatment in Kisesa, Tanzania: a follow-up study to understand attrition from the antiretroviral program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23465068" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Generalist plus specialist palliative care--creating a more sustainable model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22115794" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pain and physical and psychological symptoms in ambulatory HIV patients in the current treatment era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19811886" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Symptom experience in HIV-infected adults: a function of demographic and clinical characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24103740" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Psychological correlates of HIV-related symptom distress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20150819" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Physical and psychological symptoms and risk of virologic rebound among patients with virologic suppression on antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21377900" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Self-reported medication adherence and symptom experience in adults with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19401867" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The influence of symptom experiences and attributions on adherence to highly active anti-retroviral therapy (HAART): a six-month prospective, follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24493203" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Strategic targeting of advance care planning interventions: the Goldilocks phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26044463" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : FAmily CEntered (FACE) advance care planning: Study design and methods for a patient-centered communication and decision-making intervention for patients with HIV/AIDS and their surrogate decision-makers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9225705" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Communication of preferences for care among human immunodeficiency virus-infected patients. Barriers to informed decisions?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11401609" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : End-of-life discussions and preferences among persons with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22694717" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : HIV, aging, and advance care planning: are we successfully planning for the future?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10716022" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The effect of advance care planning on completion of advance directives and patient satisfaction in people with HIV/AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21450235" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : What factors are associated with having an advance directive among older adults who are new to long term care services?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20875170" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Factors influencing older adults to complete advance directives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16325939" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Advance care planning documents in nursing facilities: results from a nationally representative survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27398771" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Advance Care Planning and HIV Infection in the Era of Antiretroviral Therapy: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30818027" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Chronic Pain, Functional Status, and Life Satisfaction Are Associated With Patients Living With HIV Discussing Advance Care Planning With Their Family or Friends.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24316681" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Discordance in HIV-positive patient and health care provider perspectives on death, dying, and end-of-life care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30472318" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : FAmily-CEntered (FACE) Advance Care Planning Among African-American and Non-African-American Adults Living With HIV in Washington, DC: A Randomized Controlled Trial to Increase Documentation and Health Equity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24325558" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Respecting Choices®and advance directives in a diverse community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24325558" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Respecting Choices®and advance directives in a diverse community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24325558" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Respecting Choices®and advance directives in a diverse community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11834952" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9392567" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11172196" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Should patients with drug-resistant HIV-1 continue to receive antiretroviral therapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23218233" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Opioid therapies and cytochrome p450 interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23218233" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Opioid therapies and cytochrome p450 interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24621145" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Qualitative investigation of a Brief Chronic Pain Screening tool in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22766967" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Pain, mood, and substance abuse in HIV: implications for clinic visit utilization, antiretroviral therapy adherence, and virologic failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21684218" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Occurrence and characteristics of chronic pain in a community-based cohort of indigent adults living with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20210870" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Clinical and demographic variables related to pain in HIV-infected individuals treated with effective, combination antiretroviral therapy (cART).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15356788" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interagency HIV Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26119642" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Chronic Pain in HIV-Infected Patients: Relationship to Depression, Substance Use, and Mental Health and Pain Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20116299" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Risk factors and symptoms associated with pain in HIV-infected adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20116299" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Risk factors and symptoms associated with pain in HIV-infected adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29771793" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26028573" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Estimates of pain prevalence and severity in adults: United States, 2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27377620" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : United States National Pain Strategy for Population Research: Concepts, Definitions, and Pilot Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24031078" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Patterns of pain medication use during last months of life in HIV-infected populations: the experience of an academic outpatient clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25365306" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : 'Two pains together': patient perspectives on psychological aspects of chronic pain while living with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19590479" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Pain in persons living with HIV and comorbid psychologic and substance use disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25659067" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19229695" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Self-efficacy and depression as mediators of the relationship between pain and antiretroviral adherence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24119077" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Pain is independently associated with impaired physical function in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26438486" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Pain and Mortality Risk in a Cohort of HIV-Infected Persons with Alcohol Use Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25693683" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Quantitative Evaluation of an Instrument to Identify Chronic Pain in HIV-Infected Individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8080219" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Pain assessment: global use of the Brief Pain Inventory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19418100" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24033875" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Low back pain and associated imaging findings among HIV-infected patients referred to an HIV/palliative care clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14659516" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Core outcome domains for chronic pain clinical trials: IMMPACT recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29020263" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : 2017 HIVMA of IDSA Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27267445" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Pharmacologic and non-pharmacologic treatments for chronic pain in individuals with HIV: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15503108" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20124207" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18541884" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22067661" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19507807" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Methadone as an analgesic for patients with chronic pain in methadone maintenance treatment programs (MMTPs).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11223316" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Transdermal fentanyl for chronic pain in AIDS: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21642847" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Variables associated with decreasing pain among persons living with human immunodeficiency virus: a longitudinal follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30865181" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Marijuana Use Is Not Associated With Changes in Opioid Prescriptions or Pain Severity Among People Living With HIV and Chronic Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30342243" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Managing Chronic Pain in Cancer Survivors Prescribed Long-Term Opioid Therapy: A National Survey of Ambulatory Palliative Care Providers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30342243" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Managing Chronic Pain in Cancer Survivors Prescribed Long-Term Opioid Therapy: A National Survey of Ambulatory Palliative Care Providers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25581257" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21802896" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Aberrant behaviors with prescription opioids and problem drug use history in a community-based cohort of HIV-infected individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26856123" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Pain Symptoms Associated with Opioid Use among Vulnerable Persons with HIV: An exploratory study with implications for palliative care and opioid abuse prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25645646" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Pain self-management in HIV-infected individuals with chronic pain: a qualitative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26009831" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20173432" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Ongoing pain despite aggressive opioid pain management among persons with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23370078" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Association between opioid use and health care utilization as measured by emergency room visits and hospitalizations among persons living with HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21317601" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21317601" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Opioid-prescribing practices and provider confidence recognizing opioid analgesic abuse in HIV primary care settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25152300" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Guideline-concordant management of opioid therapy among human immunodeficiency virus (HIV)-infected and uninfected veterans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25394020" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Effects of age on symptom burden, mental health and quality of life amongst people with HIV in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20490910" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Patient and provider-reported symptoms in the post-cART era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25701691" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Fatigue in HIV-Infected People: A Three-Year Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19281346" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Chronicity and remission of fatigue in patients with established HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20523204" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Predictors and treatment strategies of HIV-related fatigue in the combined antiretroviral therapy era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20352317" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Physiological and psychosocial factors that predict HIV-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22998022" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : HIV-associated fatigue in the era of highly active antiretroviral therapy: novel biological mechanisms?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18608079" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Trauma, stressful life events and depression predict HIV-related fatigue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23814175" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Intensity, chronicity, circumstances, and consequences of HIV-related fatigue: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22908886" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18608084" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Measuring fatigue in people living with HIV/AIDS: psychometric characteristics of the HIV-related fatigue scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26026155" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Pharmacological treatments for fatigue associated with palliative care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10665616" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18430965" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Effects of a supraphysiological dose of testosterone on physical function, muscle performance, mood, and fatigue in men with HIV-associated weight loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15232328" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10901342" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11176767" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20492840" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21777715" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Treatment of HIV-related fatigue with armodafinil: a placebo-controlled randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15495092" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Progressive resistive exercise interventions for adults living with HIV/AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20687068" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Aerobic exercise interventions for adults living with HIV/AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12794565" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : AIDS wasting syndrome: trends, influence on opportunistic infections, and survival.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
